

1 **Pathological expansion of gut microbiome-associated**
2 ***Enterococcus* in advanced cirrhosis corresponds with multilevel**
3 **perturbations of the gut-liver-immune axis**

4 **Authors**

5 Matthew J Dalby^{1,2}, Raymond Kiu^{1,2}, Marilena Stamouli³, Betsy Arefaine³, Lex E X Leong⁴, Jack Hales⁵,
6 Christine Bernsmeier^{6,7}, Arjuna Singanayagam⁸, Sidsel Støy⁹, Maria-Emanuela Maxan^{3,6}, Merianne
7 Mohamad³, Ane Zamalloa⁶, Matt Lewis¹⁰, Royce P. Vincent^{11,12}, Roger Williams¹⁷, Lindsey A Edwards⁶,
8 Shilpa Chokshi^{3,13}, Mark Thursz^{10,14}, Naiara Beraza⁵, Charalambos G Antoniadis¹⁰, Geraint B Rogers⁴,
9 Julia A Wendon³, Kenneth D Bruce¹⁵, Debbie L Shawcross³, Mark JW McPhail^{3,6,10}, Lindsay J Hall^{1,2,5,16*},
10 Vishal C Patel^{3,6*}

11 **Affiliations**

- 12 1. Department of Microbes, Infection & Microbiomes, School of Infection, Inflammation and Immunology,
13 College of Medicine & Health, University of Birmingham, Birmingham, UK.
14 2. Institute of Microbiology & Infection, University of Birmingham, Birmingham, UK.
15 3. Roger Williams Institute of Liver Studies, School of Immunology & Microbial Sciences, Faculty of Life Sciences
16 and Medicine, King's College London, Foundation for Liver Research and King's College Hospital, London, UK
17 4. Infection & Immunity Theme, South Australian Health & Medical Research Institute, North Terrace,
18 Adelaide, SA, Australia.
19 5. Food, Microbiome and Health, Quadram Institute Bioscience, Norwich Research Park, Norwich, UK.
20 6. Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, United Kingdom
21 7. Department of Biomedicine, University of Basel, Switzerland.
22 8. Infection Clinical Academic Group, St. George's School of Health and Medical Sciences, City St. George's
23 University of London, Cranmer Terrace, London, SW17 0RE, UK.
24 9. Department of Hepatology and Gastroenterology, Aarhus University Hospital, DK-8200 Aarhus, Denmark.
25 10. Division of Digestive Disease, Department of Metabolism, Digestion & Reproduction, Imperial College
26 London, London, UK.
27 11. Department of Clinical Biochemistry, King's College Hospital NHS Foundation Trust, London, UK;
28 12. Department of Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London, London,
29 UK
30 13. Faculty of Health, University of Plymouth, Devon, UK.

1

31 14. Imperial College Healthcare NHS Trust, St Mary's Hospital, Praed St, London, UK.

32 15. Institute of Pharmaceutical Science, King's College London, UK.

33 16. Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.

34 17. *In memoriam*.

35 * Joint last and corresponding authors.

36

37 **Keywords:** Cirrhosis; Liver failure; Microbiota: *Enterococcus*; Bile acids

38 **Funding statement:** The observational study was adopted to the National Institute for Health
39 Research (NIHR) Clinical Research Network (CRN) portfolio, supporting participant screening and
40 recruitment by the Liver Research and Anaesthetics, Critical Care, Emergency and Trauma Teams at
41 King's College Hospital NHS Foundation Trust. VCP was supported by a New Investigator Award from
42 the Intensive Care Foundation (Registered charity number: 2940178) and Clinical Research Network
43 South London Principal Investigator Strategic "GreenShoot" Research Delivery and Development
44 Funding. The clinical trial was funded through an investigator-initiated study grant awarded by
45 Norgine Pharmaceuticals UK Limited to King's College London. Infrastructure to support the trial was
46 also provided by the Medical Research Council (MRC) Centre for Transplantation, King's College
47 London, UK – MRC grant no. MR/J006742/1. Laboratory assays were also part funded by a generous
48 donation from a Liver Service User to the King's College Hospital Institute of Liver Studies and
49 Transplantation Charity Research Fund, King's College Hospital Charity (Registered charity number:
50 1165593). MS, BA, MEM, MM, SC and VCP were supported and bioinformatic analyses were part
51 funded by the Foundation for Liver Research (Registered charity number: 268211/1134579). LJH is
52 supported by Wellcome Trust Investigator Award (220876/Z/20/Z); the Biotechnology and Biological
53 Sciences Research Council (BBSRC), Institute Strategic Programme Gut Microbes and Health
54 (BB/R012490/1), and its constituent projects BBS/E/F/000PR10353 and BBS/E/F/000PR10356, and
55 the BBSRC Institute Strategic Programme Food, Microbiome and Health BB/X011054/1 and its
56 constituent project BBS/E/QU/230001B. MT Acknowledges support from the NIHR-Imperial
57 Biomedical Research Centre and the Medical Research Council Precision Medicine Award
58 (MR/R014019/1).

59 **Conflicts of interest:**

60 VCP has undertaken consultancy for Norgine Pharmaceuticals Ltd, Alfasigma S.p.A. and Menarini
61 Diagnostics Ltd.

62 DLS has undertaken consultancy for Norgine Pharmaceuticals Ltd, EnteroBiotix, MRM Health, Apollo
63 Therapeutics, Genfit and Satellite Biosciences.

64 RPV reports Honoraria from Novo Nordisk, Amarin UK and AstraZeneca.

65 AS has delivered paid lectures for Bristol Myers Squibb.

66 MD, LH, RK, GR, SS, SC, KB, MJWM have no conflicts.

67 **Authors contributions:**

- 68 • Matthew J Dalby: Data curation, Formal analysis, Investigation, Software, Visualisation,
69 Writing - Original Draft, Writing - Review & Editing
- 70 • Raymond Kiu: Data curation, Formal analysis, Writing - Review & Editing
- 71 • Marilena Stamouli: Data curation, Formal analysis, Writing - Review & Editing
- 72 • Betsy Arefaine: Data curation, Formal analysis
- 73 • Lex E X Leong: Data curation, Formal analysis, Investigation, Visualization, Writing - Review &
74 Editing
- 75 • Jack Hales: Methodology, Writing - Review & Editing
- 76 • Christine Bernsmeier: Data curation, Formal analysis, Visualization, Writing - Review & Editing
- 77 • Arjuna Singanayagam: Data curation, Formal analysis, Visualization, Writing - Review &
78 Editing
- 79 • Sidsel Støy: Data curation, Formal analysis, Visualization, Writing - Review & Editing
- 80 • Maria-Emanuela Maxan: Data curation, Writing - Review & Editing
- 81 • Merianne Mohamad: Visualization, Writing - Review & Editing
- 82 • Matt Lewis: Investigation, Methodology, Writing - Review & Editing
- 83 • Royce P Vincent: Resources, Writing - Review & Editing
- 84 • Roger Williams: Supervision
- 85 • Lindsey A Edwards: Data curation, Formal analysis, Writing - Review & Editing
- 86 • Shilpa Chokshi: Supervision, Writing – review & editing

- 87 • Mark Thursz: Resources, Supervision, Writing – review & editing
- 88 • Naiara Beraza: Investigation, Resources, Writing - Review & Editing
- 89 • Charalambos G Antoniadis: Supervision
- 90 • Geraint B Rogers: Conceptualisation, Data curation, Formal analysis, Investigation, Resources,
- 91 Supervision, Visualization, Writing - Review & Editing
- 92 • Julia A Wendon: Conceptualisation, Supervision, Writing – review & editing
- 93 • Kenneth D Bruce: Conceptualisation, Supervision, Writing – review & editing
- 94 • Debbie L Shawcross: Conceptualisation, Funding acquisition, Project administration,
- 95 Resources, Supervision, Writing – review & editing, served as Chief Investigator of RIFSYS Trial
- 96 • Mark JW McPhail: Conceptualisation, Formal analysis, Supervision, Writing - Review & Editing
- 97 • Vishal C Patel: Conceptualisation, Funding acquisition, Investigation, Methodology, Project
- 98 administration, Resources, Supervision, Writing – review & editing, served as Chief
- 99 Investigator of GLA study
- 100 • Lindsay J Hall: Conceptualisation, Funding acquisition, Investigation, Methodology, Project
- 101 administration, Resources, Supervision, Writing – review & editing

102

103 **Data availability:**

104 The 16S rRNA amplicon sequencing raw reads are deposited in NCBI SRA under project
105 PRJNA1223169.

106 **Abstract**

107 **Background:** Chronic liver disease (CLD) is a progressive condition that, in its advanced stages, leads
108 to cirrhosis with related clinical complications, and can lead to acute-on-chronic liver failure (ACLF) -
109 a syndrome marked by critical illness, multi-organ dysfunction and high mortality. Systemic
110 inflammation in ACLF can occur without overt infection, indicating alternative pathways of immune
111 activation and microbial translocation. Intestinal perturbations, bacterial translocation, and the
112 resulting systemic inflammation and immune dysfunction are defining features of ACLF, yet the
113 identification of specific microbial contributors remains poorly elucidated.

114 **Objective:** To investigate the relationship between gut microbiome alterations, systemic
115 inflammation, and clinical markers of disease severity across the cirrhosis spectrum.

116 **Design:** This cross-sectional, prospective study analysed faecal microbiota, plasma bile acids, urinary
117 and plasma metabolites, markers of gut and systemic inflammation and translocation, and monocyte
118 dysfunction, in a well-phenotyped cohort of patients with ACLF, decompensated cirrhosis and stable
119 cirrhosis, in comparison with healthy individuals.

120 **Results:** Advanced stages of cirrhosis were marked by a higher abundance of *Enterococcus*, which
121 correlated with markers of systemic inflammation, particularly in ACLF patients. Concurrently, the
122 abundance of anaerobic commensal genera such as *Roseburia*, *Ruminococcus*, and *Faecalibacterium*
123 were significantly lower. Lower urinary hippurate and trimethylamine N-oxide TMAO levels, linked
124 to reduced microbial metabolism and dietary fibre intake, paralleled these microbiome changes.
125 While elevated plasma primary bile acids reflected hepatic dysfunction, systemic inflammatory
126 markers suggested parallel gut barrier dysfunction and microbial translocation in advanced cirrhosis.

127 **Conclusion:** This study underscores a potential role of greater intestinal *Enterococcus* abundance, as
128 cirrhosis severity increases and where clinically there is more antibiotic exposure, as a driver of gut
129 barrier inflammation and dysfunction, and systemic immune dysfunction in advanced cirrhosis.
130 Further research into tailored microbiome-targeted therapies, including prebiotics and probiotics,

131 and more focused antibiotic use may prevent *Enterococcus* dominance and restore gut-liver axis
132 homeostasis and mitigate disease progression in CLD.

133

134 **Key messages**

135 **What is already known on this topic:**

- 136 • CLD can progress to ACLF, a life-threatening syndrome with high mortality rates characterised
137 by systemic inflammation, impaired phagocytosis and immune dysfunction with associated
138 multiple organ failure.
- 139 • The gut microbiome's role in underpinning the gut-liver axis is recognised, with microbial
140 perturbations and gut barrier dysfunction associated with CLD, yet the exact microbiome
141 changes and their link to inflammatory pathways remain unclear.

142 **What this study adds:**

- 143 • This study reveals that *Enterococcus* significantly increases with CLD severity and antibiotic
144 use and correlates with markers of systemic inflammation and gut barrier dysfunction.
- 145 • Reductions in obligate anaerobe commensal bacteria, such as *Roseburia* and
146 *Faecalibacterium*, are observed, alongside depressed levels of key microbial metabolites,
147 including hippurate and TMAO, across CLD stages.
- 148 • These changes suggest that *Enterococcus* predominance and gut microbiome perturbations
149 driven by factors including disease severity and antibiotic use may actively drive inflammation
150 and impaired monocyte function in CLD.

151 **How this study might affect research, practice, or policy:**

- 152 • Findings indicate that *Enterococcus* and wider gut microbiome perturbations provide a
153 rationale for targeting as therapeutic strategies to modulate the gut-liver axis in CLD.

- 154
- 155
- 156
- 157
- 158
- 159
- This highlights the potential of microbiome-focused interventions, such as faecal microbial transplantation, probiotics, prebiotics or phages, to improve gut health, reduce gut and systemic inflammation, and ultimately mitigate cirrhosis-related complications.
 - Future research and development of targeted microbiome therapeutics may positively influence CLD management including a focus on antimicrobial stewardship, and inform clinical guidelines whilst improving patient outcomes.

160 **1. Introduction**

161 Chronic liver disease (CLD) is a progressive condition, resulting from several different aetiologies such
162 as alcohol, viral hepatitis, and obesity that can culminate in cirrhosis and eventual liver failure (Huang
163 et al., 2023). An important aspect of CLD is the development of acute-on-chronic liver failure (ACLF),
164 a distinct syndrome characterised by multi-organ dysfunction, worsening liver function, and liver
165 failure, with high mortality rates (Katoonizadeh et al., 2010; Moreau et al., 2013; Shah et al., 2024).
166 The transition to decompensated cirrhosis, preceding ACLF, can lack identifiable triggers,
167 confounding therapeutic options, exacerbating morbidity, and reducing transplant-free survival
168 (D'Amico et al., 2022; Trebicka et al., 2021).

169 The gut microbiota is a key component of the 'gut-liver axis' but its interplay with the disease
170 mechanisms is still not fully understood in CLD (Albillos et al., 2020; Hsu and Schnabl, 2023). While
171 bacterial infections can act as a trigger of progression to ACLF, many cases (60-70%) display systemic
172 inflammation without identifiable infection, with 50% of patients with 'sepsis' culture negative,
173 suggesting alternative inflammatory pathways and limitations in infection diagnosis methods
174 (Hernaez et al., 2017; Toledo et al., 1993). This 'sterile inflammation' in CLD patients may be driven
175 by damage-associated molecular patterns (DAMPs) released from stressed or dying hepatocytes
176 particularly in those without clear triggers such as active alcohol use or culture-confirmed bacterial
177 infections (Arroyo et al., 2015). Additionally, translocation of viable bacteria or microbial components
178 (i.e. microbial-associated molecular patterns [MAMPs]) via a dysfunctional intestinal barrier, may
179 contribute to systemic inflammation, precipitating cirrhosis-related complications. Increased
180 markers of gut permeability and inflammation in CLD patients further support the link between
181 microbial translocation and inflammatory responses (Alexopoulou et al., 2017).

182 The gut microbiota potentially plays a dual role in CLD, serving as a reservoir for pathogens and
183 MAMPs, while also simultaneously maintaining gut homeostasis through its resident commensal
184 bacteria (Adak and Khan, 2019; Caballero-Flores et al., 2023). These commensal microbes are critical
185 for gut epithelial integrity, pathobiont exclusion (and preventing overgrowth), and metabolite

186 production (e.g. short-chain fatty acids [SCFAs]) essential for host health (Ghosh et al., 2021). In CLD,
187 however, gut microbiota disruptions are frequently observed, associated with reduced intestinal
188 barrier integrity, leading to increased microbial translocation. This process introduces intestinal
189 bacteria and MAMPs into the systemic circulation, contributing to cirrhosis-related inflammation,
190 particularly in advanced disease stages. Studies in CLD have reported reductions in commensal
191 bacterial genera such as *Ruminococcus*, *Faecalibacterium*, *Bacteroidetes*, and *Coprococcus* (Da Silva
192 et al., 2018; Dubinkina et al., 2017), accompanied by increases in pathobiont taxa like
193 *Enterococcaceae*, *Staphylococcaceae*, and *Enterobacteriaceae* (Bajaj et al., 2014). Additionally,
194 patients with CLD show altered bile acid homeostasis, characterised by alterations in bile acid
195 quantities and composition, which correlate with microbiota shifts and reduced conversion of
196 primary to secondary bile acids (Kakiyama et al., 2013; Mouzaki et al., 2016), with more primary bile
197 acids being found in faeces (Kakiyama et al., 2014). These changes, mirrored in serum bile acids,
198 worsen with cirrhosis progression (Horvatits et al., 2017). However, comprehensive studies
199 integrating microbiota alterations to systemic metabolites, inflammatory and gut barrier markers,
200 across CLD stages remain limited. (Bajaj et al., 2022, 2014, 2012).

201 This study aimed to identify alterations in bacterial genera in the faecal microbiota, as targets for
202 future therapeutic intervention, across a well-phenotyped cohort of patients with ACLF,
203 decompensated cirrhosis, stable cirrhosis, and healthy controls. We aimed to understand some of
204 the potential functional properties in these microbiome changes by comparison with profiling of
205 serum bile acids, urinary and plasma metabolites, and markers of gut inflammation, bacterial
206 translocation and systemic immune activation, as key pathobiological processes within the gut-liver-
207 immune axis. We hypothesised that microbiota perturbations increase with CLD severity. By
208 correlating these microbiota differences with relevant metabolic, inflammatory, immunological and
209 clinical disease markers, we aimed to detect key target bacteria within the gut that are associated
210 with disruption within the gut-liver-immune axis, providing insights into disease pathobiology and
211 informing potential therapeutic targets.

212 **3. Results**

213 **3.1 Participant characteristics**


214 This cross-sectional cohort included patients with cirrhosis who were categorised based on disease
215 stage and severity; stable cirrhosis (SC), decompensated cirrhosis (DC), or acute-on-chronic liver
216 failure (ACLF). A healthy control (HC) group of healthy participants was included for comparison
217 analysis and to establish normal values. Table 1 summarises demographic, clinical and biochemical
218 characteristics of the recruited patients and healthy controls. A total of 153 patients with cirrhosis
219 were included in this study (SC=15, DC=81, ACLF=57) with 40 HCs. Patients with cirrhosis were older
220 than HC with a mean HC age of 38 years (SD: 10 years) and mean liver cohort age of 53 years (SD: 11
221 years). Predominant aetiologies of cirrhosis included alcohol-related liver disease (ARLD)
222 (SC/DC/ACLF: 60%/70.4%/57.9%) and metabolic- dysfunction associated steatotic liver disease
223 (MASLD) (SC/DC/ACLF: 20%/8.6%/10.5%), respectively. SC, DC and ACLF patients presented with
224 ascites (33.3%/71.6%/96.5%) and HE (6.7%/43.2%/86%) as predominant manifestations of hepatic
225 decompensation, respectively. None of the cirrhosis patients had experienced a variceal
226 haemorrhage in the 7 days prior to recruitment nor had spontaneous bacterial peritonitis at the time
227 of sampling. DC and ACLF patients were more frequently receiving antibiotics acutely (45.7%/91.2%,
228 respectively) compared to SC (20%). There was no difference in use of rifaximin- α (only five
229 participants received rifaximin- α monotherapy as antibiotic treatment), lactulose, non-selective
230 beta-blockers and acid suppression therapies (proton pump inhibitors, H2 antagonists) across the
231 cirrhosis cohorts. Haematological, biochemical and disease severity and prognostic composite scores
232 followed expected patterns. Transplant-free survival at 90 days was 77.8% and 24.6% for the DC and
233 ACLF groups, respectively, with no deaths observed in the SC group.

234 **3.2. Microbiota diversity, bacterial translocation, faecal calprotectin, serum bile acid, and**
235 **metabolites profiles are progressively altered with increasing cirrhosis severity.**

236 Initial analysis focused on the composition of the faecal microbiota, plasma bile acids, urinary
237 metabolites and serum metabolites between cirrhosis severity groups in comparison to HCs. Faecal
238 microbiota diversity, both the number of bacterial genera detected (**Figure 1A**) and the Inverse
239 Simpson diversity index (**Figure 1B**), was lower in patients with more advanced cirrhosis compared
240 to all other groups. Clustering analysis using non-metric multidimensional scaling (NMDS) shows
241 separation in gut microbiota composition between ACLF and HC, with DC clustered between HC and
242 ACLF, while SC clustered closely to HC (**Figure 1C; Supplementary File 2**). The overall effect of disease
243 severity was tested using a PERMANOVA test ($R^2 = 13.5\%$; $P = 0.0001$) and a pairwise comparison
244 showed that the ACLF group clustered separately ($P < 0.05$) from DC, SC, and HC groups with DC also
245 different to the HC group (**Supplementary File 6**). To assess the associations between clinical
246 metadata variables, NMDS analysis was specifically conducted on faecal sequencing data from
247 patients with cirrhosis excluding HCs. Envfit analysis was used to examine the influence of 69 clinical
248 variables on microbiota composition. Forty-one clinical variables were significantly associated with
249 microbiota composition in patients with cirrhosis, with measures of cirrhosis severity exhibiting the
250 most pronounced impact (**Supplementary Figure 1A; Supplementary File 7**). For the purposes of
251 visualisation the ten clinical variables with the highest R^2 values with the strongest association with
252 the microbiota composition were overlaid on the NMDS plot and were all correlated with cirrhosis
253 severity (**Supplementary Figure 1B; Supplementary File 7**).

254 NMDS plots comparing plasma bile acid composition indicated higher divergence amongst HC
255 samples, and an increasing convergence (clustering) with cirrhosis severity (PERMANOVA: $P=0.0001$)
256 (**Figure 1D; Supplementary File 3,6**). Both urine (PERMANOVA: $P=0.0001$) and plasma metabolites
257 (PERMANOVA: $P=0.0001$) showed significant separation in clustering based on cirrhosis severity with
258 similar NMDS clustering with tightly clustered HC samples and divergent cirrhosis patient samples,
259 particularly for ACLF (**Figure 1E-F; Supplementary File 6**). Multivariate analysis, after obvious
260 exclusions including for dominant glucose or ethanol peaks, for example, showed separation of the
261 four study cohorts (HC, $n=36$; SC, $n=8$; DC, $n=67$; and ACLF, $N=36$) with pairwise multilevel comparison
262 showing significant differences between all groups except SC and DC ($P < 0.05$). This was also

263 confirmed visually by the NMDS plots (**Figure E; Supplementary File 5**) and relative metabolite levels
264 per grouping for TMAO, hippurate (**Figure 3F; Supplementary File 6**) and for creatinine, citrate,
265 dimethylamine, formate and mannitol (**Supplementary Figure 3**).



266


267 **Figure 1: Comparison of faecal microbiota diversity, plasma bile acids, and metabolites profiles in**
268 **cirrhosis and healthy controls.**

269 (A) Number of genera detected in each participant's faecal sample by cirrhosis severity and HC. (B)
270 Faecal microbiota diversity measured using the Inverse Simpson diversity index by cirrhosis severity
271 vs HC. NMDS ordination shows dissimilarity indices via Bray-Curtis distances between individual
272 participants coloured by cirrhosis severity vs HC (D) plasma bile acids (E) urinary metabolites and (F)

273 serum metabolites. Dot and box plots show median and interquartile ranges of data with circles
274 showing each individual participant.

275 **3.3. Genus-level microbiota composition at different cirrhosis severities reveals a progressive**
276 **overabundance of *Enterococcus* with reductions in commensal taxa.**

277 To investigate alterations in gut microbiota composition in more detail, bacterial genus profiles
278 within individual participants were examined. Stacked bar plots showing the ten most abundant
279 bacterial genera illustrate an increasing dominance of *Enterococcus* in more advanced cirrhosis i.e.
280 DC and ACLF groups (**Figure 2A**). Differential abundance of bacterial genera is represented in a heat
281 map showing significant associations between faecal bacterial genera comparing the three cirrhosis
282 groups with HC (**Figure 2B; Supplementary file 8**). *Ruminococcus*, *Roseburia*, and *Lachnospira*
283 showed the strongest negative association with cirrhosis severity with the lowest abundances in ACLF
284 and DC patients compared to HC (**Figure 2C-E**). *Enterococcus* and *Staphylococcus* showed the
285 strongest positive association with cirrhosis severity with highest abundance in ACLF relative to HC
286 (**Figure 2FH**), while *Streptococcus* abundance was higher in DC and SC compared to HC (**Figure 2G**).
287 *Enterococcus* abundance was markedly higher in the ACLF patient group compared to HC (**Figure 2C**).
288 Conversely, a proportion of more severely ill patients with cirrhosis have gut microbiota dominated
289 by *Enterococcus*, with significantly elevated levels observed in DC and ACLF. In a quarter of ACLF
290 patients, the relative abundance of *Enterococcus* exceeded 75%.



291

292 Figure 2: Microbiota genus composition in cirrhosis vs. healthy controls.

293 (A) Stacked bar plots show the ten most abundant bacterial genera in faecal samples stacked by
294 overall abundance, and with participants ordered within cirrhosis severity categories by proportion
295 of *Enterococcus*. (B) The heat map displays MaAslin2 analysis of significant associations between
296 faecal genus abundance and cirrhosis severity with HC used as a reference. The three genera with
297 the strongest negative effect size for cirrhosis severity determined by MaAslin2 using HC as a
298 reference and shown as box and dot plots were (C) *Ruminococcus*, (D) *Roseburia*, and (E) *Lachnospira*.
299 The three genera with the strongest positive effect size for cirrhosis severity determined by MaAslin2
300 using HC as a reference and shown as box and dot plots were (F) *Enterococcus*, (G) *Streptococcus*,
301 and (H) *Staphylococcus*. Dot and box plots show median and interquartile ranges of data with circles
302 showing each individual participant.

303 **3.4. Plasma bile acids and urinary metabolites correlate with specific gut microbiota taxa with** 304 **increasing cirrhosis severity.**

305 To determine the impact of cirrhosis severity on alterations in plasma bile acids, urinary metabolites,
306 and serum metabolites, we correlated these, using MaAsLin2, with faecal bacterial genera to
307 investigate their associations with gut microbiota composition and provide putative insights into
308 alterations in microbiome function. The primary bile acids taurochenodeoxycholic acid (TCDCA),
309 glycochenodeoxycholic acid (GCDCA), taurocholic acid (TCA) and glycocholic acid (GCA) were higher
310 in the plasma of patients with cirrhosis compared to HC, while other bile acids were lower than in HC
311 (**Figure 3A; Supplementary File 9**). TCDCA and GCDCA showed the strongest effect size with higher
312 concentrations in all three cirrhosis cohorts relative to HC (**Figure 3B-C; Supplementary Figure 3**).
313 Contrasting plasma bile acid concentrations with the percentage of bacterial genera showed that
314 *Enterococcus* abundance was positively correlated with primary bile acids including TCDCA, while
315 *Ruminococcus*, *Coprococcus*, and *Roseburia* were negatively correlated with primary bile acid
316 concentration (**Figure 3D; Supplementary Figure 2**).


317 Analysis of urinary metabolites showed several metabolites differing by cirrhosis severity relative to
318 HC (**Figure 3E; Supplementary File 10**). Two metabolites, hippurate (**Figure 3F**) and Trimethylamine

319 N-oxide (TMAO) (**Figure 3G**), were identified as products of gut microbial metabolism and both were
320 lower in patients with cirrhosis compared to HC, and lower in ACLF than in SC or DC (**Figure 3F-G**;
321 **Supplementary Figure 2**). Contrasting urinary metabolites with the percentage proportion of
322 bacterial genus showed that *Enterococcus* abundance was negatively correlated with several
323 metabolites including hippurate and TMAO, while *Ruminococcus*, *Coprococcus*, and *Roseburia* were
324 positively correlated with hippurate and TMAO (**Figure 3H**; **Supplementary Figure 3**).

325 Similar differences were seen in plasma metabolites with significant differences between cirrhosis
326 cohorts and HC (**Supplementary Figure 4A**; **Supplementary File 11**) amongst several plasma
327 metabolites (**Supplementary Figure 4B-G**). Similarly, *Enterococcus* abundance correlated with
328 changes in a number of plasma metabolites (**Supplementary Figure 4H**).

329 These findings show a pattern characterised by elevated concentrations of primary bile acids in
330 plasma and reduced quantities of recognised microbial metabolites in the urine among cirrhosis
331 patients with more advanced disease.

332



333

334 **Figure 3: Plasma bile acids, urinary metabolites, and correlations with abundance of faecal**
 335 **bacterial genera.**

336 (A) The heatmap displays MaAslin2 analysis results of significant associations between plasma bile acid concentrations and cirrhosis cohorts using HC as a reference. The two plasma bile acids with the
 337 strongest positive effect size for cirrhosis severity determined by MaAslin2 using HC as a reference
 338 and shown as box and dot plots were (B) Taurochenodeoxycholic acid and (C) Glycochenodeoxycholic
 339 acid. (D) Pearson correlations between the normalised relative abundance of the top twenty most
 340

341 abundant faecal bacterial genera (comprising 98% of the microbiota) and normalised plasma bile acid
342 concentrations showing bile acids with significant correlations. (E) The heatmap displays MaAslin2
343 analysis results of significant associations between urinary metabolite concentrations and cirrhosis
344 severity using HC as a reference. The two urinary metabolites with the strongest negative effect size
345 for cirrhosis severity determined by MaAslin2 using HC as a reference and shown as box and dot plots
346 were (F) Trimethylamine N-oxide (TMAO) and (G) Hippurate. (H) Pearson correlations between the
347 normalised relative abundance of the top twenty most abundant faecal bacterial genera (comprising
348 98% of the microbiota) and normalised urinary metabolite concentrations showing metabolites with
349 significant ($P < 0.05$) correlations. Full correlations shown in Supplementary Figure 3 and 4.

350 **3.5. Clinical variables link to overall microbiota profiles, with further associations in advanced** 351 **cirrhosis of *Enterococcus* with antibiotic usage and resistance profiles**

352 Next, we carried out an exploratory analysis to determine how clinical parameters might be
353 associated with gut microbiota composition, using the envfit function, focusing on each clinical
354 variable and overall microbiota beta-diversity. The ten clinical variables with the strongest
355 association with faecal microbiota composition were plotted overlaying an NMDS plot
356 (**Supplementary Figure 1**). Several clinical factors correlated with microbiota composition, with
357 conventional measures of cirrhosis severity showing the strongest association (**Supplementary**
358 **Figure 1, Supplementary File 7**). Composite clinical scores are used to classify cirrhosis severity and
359 for prognostication. Of those included in this analysis, ACLF grade, MELD score, Child-Pugh grade and
360 score, and UKELD score were all associated with microbiota composition, in keeping with the study
361 phenotyping of the cirrhosis cohorts, i.e. SC, DC, and ACLF.

362 Antibiotic use, oral food intake, and lactulose use were clinical variables identified as both having an
363 association with microbiota composition, and considered likely to have a direct influence on the gut
364 microbiota (**Supplementary File 2**). Differential abundance testing was carried out using MaAslin2
365 for antibiotic use, oral food intake, and lactulose use along with cirrhosis severity was included within
366 the MaAslin2 model to adjust for covariance (**Supplementary File 12**). Antibiotic use, oral food intake,

367 lactulose use, all showed significant effects on differential abundance of genus within the patient
368 cohort when adjusted for covariance. Comparing the genus with the large difference in abundance
369 in cirrhosis patients receiving or not receiving enteral intake, *Roseburia* abundance was lower in
370 patients not receiving nutrition *via* enteral routes (normal oral intake and by enteral tube feeding),
371 while *Enterococcus* abundance was higher (**Figure 4A**). Similarly, *Roseburia* abundance was lower in
372 patients receiving antibiotics, while *Enterococcus* abundance was higher (**Figure 4B**). Results were
373 unchanged when excluding the 5 patients only receiving rifaximin as antibiotic treatment. Lactulose
374 use was associated with a higher relative abundance of *Bifidobacterium* within the patient cohort
375 between those receiving lactulose and those not (Figure 4E). *Enterococcus* remained significantly
376 higher abundance in DC and ACLF severity groups compared to HC when adjusted for antibiotic use,
377 oral food intake indicating an independent effect of all three factors on *Enterococcus* abundance
378 (**Supplementary Table 2**).

379 The cirrhosis group as a whole received a total of 19 different types of antibiotics (**Figure 4F**;
380 **Supplementary Table 2**). The most frequently used antibiotics were piperacillin/tazobactam (Tazocin)
381 (33 patients) and 16 Meropenem (16 patients) totalling 37% of patients while 48 (36%) received no
382 antibiotics. The remaining 17 antibiotics were given to 6 or fewer patients with 8 antibiotics only
383 given to one patient. To visualise the complexities of this antibiotic administration, data was
384 visualised as a heatmap with patients clustered by antibiotic use and antibiotics clustered by co-
385 occurrence (**Figure 4C**). Associations of gut bacterial genus differential abundance with all individual
386 antibiotic administration was tested in a MaAsin2 model with only piperacillin/tazobactam (Tazocin)
387 and meropenem individually associated with abundance of *Enterococcus* (**Supplementary Table 8**
388 **Figure 4C**). Five out of 48 patients not currently receiving antibiotics also showed higher *Enterococcus*
389 relative abundance (**Figure 4C**). This cirrhosis cohort included a range of aetiologies, however, cause
390 of cirrhosis did not significantly associate with gut microbiota composition. Rather, cirrhosis severity,
391 antibiotics, and nutritional intake use was the primary factor that co-associated with a dominant
392 *Enterococcus* gut microbiota signature in patients with most severe disease i.e. DC and ACLF
393 (**Supplementary figure 7AB**).


394 To probe *Enterococcus* traits in more detail, five isolates obtained from five different patient faecal
395 samples (one sample from the DC cohort and four from the ACLF cohort) underwent whole genome
396 sequencing and were identified as *Enterococcus faecium*. Comparing the similarities of these 5 novel
397 isolates with an additional publicly available 185 *E. faecium* genomes (retrieved from the NCBI
398 GenBank database) using midpoint rooted maximum-likelihood tree showed a diversity of *E. faecium*
399 genomes with no single clonal group colonising patients with cirrhosis indicating that the *E. faecium*
400 isolates did not originate from the same source (**Figure 4D**). The five *E. faecium* cirrhosis isolate
401 genomes were aligned against virulence-related gene profiles, antibiotic resistance genes, and bile
402 resistance genes (**Figure 4E**). These isolates contained between 12 and 17 of the 20 antibiotic
403 resistance genes analysed (**Figure 4E**); 5 genes encoding aminoglycoside resistance, 7 *van* genes
404 encoding vancomycin resistance, 3 encoding macrolides resistance, 2 encoding tetracycline
405 resistance, and 2 trimethoprim resistance. The two bile acid resistance genes *bsh* and *gltK* were
406 present in all patient isolates, and in the genomes of 95% of all 190 isolates from public databases
407 (**Figure 4F**).

408 Taken together, these data indicate that clinical factors such as reduced enteral nutritional intake
409 and exposure to the broad-spectrum beta-lactam antibiotics piperacillin/tazobactam (Tazocin) and
410 meropenem were strongly linked to higher levels of *Enterococcus* and decreased abundance of
411 commensal genera in patients with cirrhosis. Broad-spectrum beta-lactam antibiotics are commonly
412 administered to DC and ACLF patients as part of their treatment regimen. *Enterococcus* isolates
413 obtained and sequenced from these patients were identified as *E. faecium* and were found to encode
414 various antibiotic and bile acid resistance genes, indicating potential bacterial survival mechanisms
415 and pathogenicity.

416

417

418



420 **Figure 4: Oral food intake, receiving antibiotics, and *Enterococcus faecium* genomic data.**

421 The differentially abundant genera with the strongest negative and positive effect sizes for antibiotics
422 with patients not receiving antibiotics as the reference were (A) *Ruminococcus* and (B) *Enterococcus*.
423 The differentially abundant genera with the strongest negative and positive effect sizes for nutritional
424 intake with patients not receiving enteral as the reference were (C) *Roseburia* and (D) *Enterococcus*.
425 The differentially abundant genera with the strongest positive effect size for lactulose use with
426 patients not receiving lactulose as the reference was (E) *Bifidobacterium*. (F) Clustered individual
427 antibiotics received by patients with cirrhosis cohort, nutritional status, and relative abundance of
428 *Enterococcus* in each sample. (G) A midpoint rooted maximum-likelihood tree consisted of 190
429 *Enterococcus faecium* genomes, including 5 novel *E. faecium* isolates obtained from cirrhosis
430 patients, as highlighted in the tree. (H) Novel *E. faecium* genomes (n=5) from cirrhosis patients
431 aligned with virulence-related gene profiles, virulence (using VFDB), ARG (Antibiotic Resistance
432 Genes; using ARG-ANNOT) and bile resistance genes (*bsh* and *gltK*), accordingly. Proportion of
433 *Enterococcus* (genus level; based on 16S rRNA sequence data) in the corresponding faecal samples
434 was also indicated in the horizontal bar chart. (I) Proportion of detectable bile resistance genes (%)
435 *bsh* and *gltK* in 190 *E. faecium* genomes, suggesting that these two genes belong to the core genome
436 of *E. faecium*.

437 **3.6. Faecal microbiota and markers of bacterial translocation, intestinal and systemic**
438 **inflammation, and monocyte exhaustion.**

439 To explore links between gut barrier dysfunction and translocation of intestinal bacteria and/or their
440 products from the gut into the systemic circulation, we determined the number of copies of 16S rDNA
441 in whole blood from cirrhosis patients and HC. The number of copies of 16S rDNA in the blood was
442 lowest in HC in keeping with a degree of 'physiological translocation' and displayed a stepwise
443 increase with severity of cirrhosis (**Figure 5A**). To identify associations with the faecal microbiota, we
444 correlated copies of 16S rDNA in the blood against percentages of bacterial genera (**Figure 5B**), with
445 *Enterococcus* most strongly positively correlated (**Figure 5C**), and *Lachnospira* most negatively


446 correlated (**Figure 5C**). Faecal calprotectin as a conventional marker of non-specific gut mucosal
447 inflammation also showed a stepwise increase with cirrhosis severity compared to HC (**Figure 5D**).
448 Faecal calprotectin was positively correlated with relative abundance of *Enterococcus* (**Figure 5E**) and
449 negatively correlated with *Lachnospira* (**Figure 5E**).

450 The innate immune function of CD14⁺ monocytes isolated from peripheral blood obtained from
451 cirrhosis patients and HCs was assessed by stimulation with TLR 2/4/9 agonists *in vitro*, with
452 unstimulated controls, and the percentage of Tumour necrosis factor-alpha (TNF- α), Interleukin-6
453 (IL-6), and monocyte human leukocyte antigen-DR (HLA-DR) positive monocytes identified by flow
454 cytometry. Monocytes from DC and ACLF patients showed attenuated proinflammatory responses
455 (TNF- α and IL-6) to Pam3, LPS and CpG challenge, indicating reduced innate responses to pathogen-
456 induced TLR signalling pathways. (**Supplementary Figure 1**). To identify cirrhosis-associated
457 alterations in monocyte function and associations with factors linked to the microbiota, the
458 percentage of TNF- α or IL-6 positive monocytes were correlated with copies of 16S rDNA in whole
459 blood, faecal calprotectin, and the twenty faecal genera with the highest overall abundance (**Figure**
460 **5I**; **Supplementary Figure 6**). The number of copies of bacterial DNA in whole blood positively
461 correlated with the percentage of IL-6 positive unstimulated monocytes, while the number of genera
462 positively correlated with the percentage of TNF- α and IL-6 positive LPS-stimulated monocytes
463 (**Figure 5I**). *Lachnospira* showed positive associations and *Enterococcus* negative associations with
464 the percentage of TNF- α and IL-6 positive LPS stimulated monocytes (**Figure 5J**) and *Enterococcus*
465 with TNF- α positive Pam3 stimulated monocytes (**Figure 5IK**).

466 These findings reveal contrasting associations between *Enterococcus* and other commensal bacterial
467 genera, such as *Lachnospira*, on markers of intestinal permeability, intestinal and systemic
468 inflammation, and monocyte innate immune function.

469

470



471

472 **Figure 5. Markers of intestinal permeability and intestinal inflammation and correlations of**
 473 **stimulated monocyte activation with (whole) blood 16S rDNA and faecal microbiota.**

474 (A) Copies of 16S rDNA in participant blood by cirrhosis severity vs HC. (B) Significant correlations
475 between copies of 16S rDNA in participant blood and percentage of genera in the faecal microbiota.
476 (C) Scatter plot of copies of 16S rDNA in blood against faecal *Enterococcus* for each participant. (D)
477 Scatter plot of copies of 16S rDNA in blood against faecal *Lachnospira* for each participant. (E) Faecal
478 calprotectin concentration by cirrhosis severity vs HC. (F) Significant correlations between faecal
479 calprotectin concentration and percentage of genera in the faecal microbiota. (G) Scatter plot of
480 faecal calprotectin concentration against faecal *Enterococcus* percentage for each participant. (H)
481 Scatter plot of faecal calprotectin concentration against faecal *Lachnospira* percentage for each
482 participant. (I) Percentage of monocytes showing TNF- α and IL-6 production and HLA-DR expression
483 in response to antigen stimuli (LPS/TLR-4; Pam3CSK4/TLR-2, CpG/TLR-9) correlated separately with
484 whole blood 16S rDNA, number of faecal genera, faecal *Enterococcus* percentage and faecal
485 *Lachnospira* percentage. Stars (*) indicate statistical significance ($P < 0.05$) after adjustment for
486 multiple testing. (J) Scatter plot of percentage of TNF-alpha positive LPS stimulated monocytes
487 against faecal *Enterococcus* percentage for each participant. (K) Scatter plot of percentage of TNF-
488 alpha positive PAM3 stimulated monocytes against faecal *Enterococcus* percentage for each
489 participant.

490

491

492 **4. Discussion**

493 We found higher relative abundance of *Enterococcus* in the gut microbiota of patients with cirrhosis,
494 particularly in those with advanced disease and receiving broad spectrum antibiotics, accompanied
495 by a lower abundance of obligate anaerobic commensal genera. This shift is consistent with patterns
496 seen in other conditions with compromised intestinal barrier function, such as preterm infants
497 (Hufnagel et al., 2007) and Graft-versus-Host Disease (Garrett, 2020), as well as other studies in ACLF
498 (Lee et al., 2024a, 2024b; Solé et al., 2021). These findings suggest that *Enterococcus*, an
499 opportunistic pathogen, may exploit disrupted gut microbial communities and diminished
500 colonisation resistance to thrive, especially in advanced disease states with multiple gut microbiota
501 modulating treatments.

502 Multiple factors may contribute to the selection and proliferation of resident *Enterococcus* strains in
503 the gut of cirrhosis patients. Antibiotic use is one such factor, as many of the patients with high
504 *Enterococcus* levels had received broad-spectrum beta-lactam antibiotics like
505 Piperacillin/tazobactam or meropenem. These antibiotics are commonly administered to
506 hospitalised DC and ACLF patients for treating suspected infections, often before culture results are
507 available, and *Enterococcus* exhibits intrinsic resistance to beta-lactam antibiotics (Zapun et al.,
508 2008), potentially providing a selective advantage. Additionally, the *E. faecium* isolates in this study
509 encoded genes conferring bile acid resistance (Zhang et al., 2013), which may further facilitate
510 persistence in the bile-rich environment characteristic of advanced cirrhosis (Kakiyama et al., 2013).
511 Elevated intestinal luminal bile acids in cirrhosis, particularly primary bile acids, can alter the gut
512 microbial environment (Ridlon et al., 2013), often reducing bile-sensitive commensals like *Roseburia*
513 and providing an ideal niche for *Enterococcus* to overgrow.

514 This relative overgrowth of *Enterococcus* in the gut microbiota, especially strains with virulence genes
515 like *acm* and *sgrA* (encoded in all strains isolated from this study cohort), which enhance adhesion
516 and translocation, presents significant clinical implications. These strains may be associated with
517 systemic infections that can exacerbate cirrhosis-related complications, such as progression from a

518 stable state to DC and ACLF (Hendrickx et al., 2009; Nallapareddy et al., 2008). Moreover, bacterial
519 sepsis is a significant complication in patients with cirrhosis, an increasing recognition of the threat
520 of antimicrobial resistance (Piano et al., 2019; Wong et al., 2021). Carriage of multidrug resistant
521 strains (as indicated by our genomic analysis) may contribute to greater clinical complication
522 episodes by way of hepatic decompensation, organ failure and mortality rates, due to increased
523 translocation of *Enterococcus* via a dysfunctional and inflamed gut barrier into the bloodstream.
524 Furthermore, as *Enterococcus* appears to dominate more severely ill patients to the exclusion of
525 other potential pathogens, this pattern raises questions about its source. Genomic analysis showed
526 divergent strains of *E. faecium* were present in patients rather than any common clonal lineages,
527 which would be the case if multiple patients had acquired the *E. faecium* from each other or from
528 the same hospital environment. This indicated that the *E. faecium* are more likely to represent
529 resident gut strains already in the patient rather than nosocomial infections. Further investigation
530 involving a larger number of isolates will be valuable to confirm these findings.

531 As faecal *Enterococcus* abundance increased, we observed a corresponding significant decline in key
532 commensal bacterial genera including *Roseburia*, *Ruminococcus*, *Coprococcus*, and *Faecalibacterium*,
533 with many ACLF patients showing an almost complete relative absence. These genera are essential
534 for SCFA production, such as butyrate (Flint et al., 2012), which supports intestinal barrier integrity.
535 The loss of these beneficial microbes is a common feature in cirrhosis (Acharya and Bajaj, 2019) that
536 is linked to the development of gut barrier failure, pathological microbial translocation and cirrhosis-
537 associated immune dysfunction. Their decline appears to be further exacerbated by common
538 therapeutic factors in the treatment of advanced cirrhosis, such as the use of broad-spectrum
539 antibiotics, which impact antibiotic-sensitive species (Zimmermann and Curtis, 2019), and a reliance
540 on fibre-deficient diets, particularly among patients dependent on enteral or parenteral nutrition
541 (present in 45% of the ACLF group). These diets lack the necessary fermentable dietary fibre to
542 sustain SCFA-producing microbes, worsening microbial disruption and potentially contributing to gut
543 permeability.

544 This microbiota disruption is mirrored by lower urinary levels of metabolites like hippurate which is
545 a products of beneficial microbial metabolism and fibre-rich diets (Lees et al., 2013) and TMAO, which
546 is a microbial byproduct or metabolising nutrients including choline, betaine, and carnitine found in
547 meat, eggs, and fish (Pallister et al., 2017). Hippurate production, often associated with microbial
548 metabolism of phenolic compounds in fruits and vegetables, was positively correlated with
549 *Ruminococcus*, further linking microbial loss with decreased metabolic activity. Similarly, TMAO -
550 produced via hepatic conversion of trimethylamine (TMA), itself a microbial metabolite from dietary
551 sources like carnitine and lecithin - was also reduced, indicating either a reduction in dietary
552 substrates or a loss of the bacteria producing TMA or potentially a loss of liver function to convert
553 TMA into TMAO (van den Berg et al., 2023). Reduced *Ruminococcus* abundance correlated with
554 decreased urinary TMAO, reflecting not only microbial shifts but also dietary limitations and potential
555 hepatic enzymatic changes (FMO1 and FMO3) seen in advanced cirrhosis (Organ et al., 2020)
556 (Gatarek and Kaluzna-Czaplinska, 2021; Williams et al., 2010). These data suggest that microbial and
557 dietary disturbances may jointly contribute to the metabolic and immune challenges observed in
558 cirrhosis progression.

559 Further, we noted that patients with cirrhosis exhibited elevated plasma bile acids, especially
560 glycochenodeoxycholic and TCDCA, which correlated with cirrhosis severity. This increase likely
561 stems from impaired hepatic bile acid uptake and reduced conversion to secondary bile acids due to
562 the loss of deconjugating genera like *Lachnospiraceae* and *Ruminococcaceae* genera that were
563 significantly depleted in this cirrhosis cohort (Vital et al., 2019). This impaired conversion could
564 further favour the persistence of *Enterococcus*, as elevated primary bile acids can disrupt the gut
565 microbial ecosystem and inhibit commensal bacteria.

566 Consistent with microbial translocation in cirrhosis, we observed elevated copies of 16S rDNA in the
567 systemic circulation of patients, correlating with cirrhosis severity and reflecting gut barrier
568 dysfunction (Albillos et al., 2022). This microbial translocation, along with elevated faecal calprotectin
569 concentrations, and associated breakdown of gut barrier function and integrity in cirrhosis (Riva et
570 al., 2020), linking with loss of key butyrate-producing microbes like *Ruminococcus* and

571 *Faecalibacterium* genera in DC and ACLF patients (Fagan et al., 2015) (Bach Knudsen et al., 2018).
572 Reduced faecal short-chain fatty acids have been previously reported (Jin et al., 2019; Wang et al.,
573 2023), and a reduced capacity to ferment dietary fibre in cirrhosis patients compared to healthy
574 controls (Jin et al., 2019). *Enterococcus*, which correlated strongly with 16S rDNA copies in the blood,
575 and gut inflammation markers like faecal calprotectin, indicates its likely role in gut inflammation and
576 immune activation in these patients. In cirrhosis, the progressive loss of intestinal barrier integrity
577 allows MAMPs, and viable bacteria, like *Enterococcus*, to translocate into the bloodstream, triggering
578 systemic inflammation and further impairing immune function (Tilg et al., 2022). Indeed, previous
579 work in mice indicates that *E. faecium* triggers colonic cytokine expression, which appears to be strain
580 dependent (Seishima et al., 2019) and related to elevated faecal cytokine levels and other markers
581 of gut barrier dysfunction in DC patients (Riva et al., 2020). Conversely, *Lachnospira* were markedly
582 reduced in cirrhosis patients (Abdugheni et al., 2022), potentially resulting in the loss of the
583 protective role of SCFAs that dampen mucosal immune activation such as through activation and
584 maturation of T regulatory cells (Y et al., 2013). Coupled with impaired immune responses to
585 pathogen-associated TLR signalling, as observed in the CD14+ monocytes of cirrhotic patients, this
586 suggests a vicious cycle of gut perturbations, immune dysfunction, and bacterial translocation that
587 exacerbates systemic inflammation.

588 Interestingly, despite the widespread antibiotic use in the DC and ACLF patients, *Bifidobacterium*
589 persisted in the microbiota of patients with cirrhosis. This genus is typically considered sensitive to
590 antibiotic use (Moubareck et al., 2005), so its resilience here may be due to the frequent use of
591 lactulose, a non-absorbable disaccharide laxative often prescribed to prevent or treat hepatic
592 encephalopathy. Lactulose acts as a prebiotic, providing a substrate that *Bifidobacterium* can
593 metabolise, thereby promoting its growth. Recent studies have shown lactulose can elevate
594 *Bifidobacterium* levels in cirrhosis patients, which inhibited the antibiotic-resistant pathobiont
595 vancomycin-resistant *E. faecium* through potential mechanisms including lowering the luminal pH
596 and via acetate production (Odenwald et al., 2023). Our results add to these recent findings that

597 lactulose supplementation could help support *Bifidobacterium* populations in patients with cirrhosis
598 (Odenwald et al., 2023).

599 From a therapeutic perspective, restoring the gut microbiota toward a healthier balance, or
600 “eubiosis”, could mitigate the cycle of immune dysfunction and prevent cirrhosis-related
601 complications (Tranah et al., 2021). Dietary or microbial interventions, such as prebiotics, probiotics,
602 or microbiome-targeted treatments, could offer a promising approach. While faecal microbiota
603 transplantation is currently being trialled (e.g. ClinicalTrials.gov: NCT02862249, NCT06461208,
604 NCT04932577), it carries risks for patients with advanced cirrhosis, where highly personalised or
605 targeted microbiome interventions may be safer (Cibulková et al., 2021) and use of Cefepime to
606 protect anaerobes in gut vs Pip Taz / meropenem. Probiotics or prebiotics aimed at restoring
607 beneficial taxa lost in cirrhosis, such as *Roseburia*, could help inhibit *Enterococcus* overgrowth,
608 reinforce intestinal barrier integrity, and reduce inflammation. However, these approaches are not
609 available yet clinically or commercially, and significant investment and development is needed to
610 bring such novel, next-generation microbiome-modulating therapies to benefit this patient
611 population. This highlights the urgency for better antimicrobial stewardship and the development of
612 rapid diagnostics that can better target potential pathogens while reducing the use of broad
613 spectrum antibiotics and deescalating to avoid prolonged courses of exposure.

614 Our findings raise the possibility that the overgrowth of *Enterococcus* and loss of commensal
615 microbiota may not merely correlate with disease severity, and associated conventional therapies
616 such as the use of antibiotics and absence of a dietary fibre may also contribute to disease
617 progression. However, our cross-sectional study design and single time-point sampling limit our
618 ability to infer causality. Longitudinal studies, combined with animal models, could further clarify
619 whether *Enterococcus* contributes to pathological processes in cirrhosis or is an opportunistic
620 response to the disrupted gut environment. Additionally, refined antibiotic strategies, possibly
621 reducing the selective pressure for *Enterococcus*, alongside targeted dietary support to foster
622 beneficial microbes, may represent viable options to improve outcomes for these high-risk patients.

623 **7. Acknowledgements**

624 We are grateful to all the patient participants and healthy volunteers for agreeing to take part in this
625 study, and to the clinical and liver research teams at King's College Hospital for facilitating
626 recruitment, collecting metadata and biological sample collection. We thank the King's College
627 Hospital Charity and a generous donation from a Liver Service User, and the Foundation for Liver
628 Research for funding. Sequencing analysis was supported in part by the NBI Research Computing
629 through the provision of a High Performance Computing. The authors thank the Centre for
630 Biomolecular Spectroscopy funded by the Wellcome Trust and British Heart Foundation (ref.
631 202767/Z/16/Z and IG/16/2/32273).

632

633 **Supplementary methods**

634 **Study participants & biological sampling**

635 Patient participants were stratified and phenotyped according to clinically relevant groups based on
636 the severity and time course of their underlying cirrhosis, degree of hepatic decompensation, and
637 presence and extent of hepatic and extra-hepatic organ failure at the time of sampling. These groups
638 were stable cirrhosis (SC; n=15), decompensated cirrhosis (DC; n=55) and acute-on-chronic liver
639 failure (ACLF; n=57), with a separately recruited healthy control cohort (HC; n=40). SC was defined as
640 having Child Pugh A grade(score) of A(5-6). DC was defined by the acute development of 1 or more
641 major complications of cirrhosis, including ascites, HE, variceal haemorrhage, and bacterial infection.
642 ACLF was defined and graded according to the number of organ failures in concordance with criteria
643 reported in the CANONIC study (Arroyo et al., 2015; Moreau et al., 2013). Main exclusion criteria
644 included pregnancy, hepatic or non-hepatic malignancy (HCC within Milan criteria were included),
645 pre-existing immunosuppressive states, replicating HBV/HCV/HIV infection, and known inflammatory
646 bowel disease. Further details are provided in the Supplementary section.

647 Patients were consecutively recruited at King's College Hospital after admission to the ward or when
648 reviewed in the hepatology out-patient clinic, through an observational study and a clinical trial. The
649 observational study was granted approval by the NHS Health Research Authority NRES Committee
650 London Westminster [REC reference: 12/LO/1417] and local sponsor Research and Development
651 department (KCH12-126). Ethical approval for the interventional trial was obtained from NHS Health
652 Research Authority NRES Committee South Central-Oxford C (Bristol) [REC reference: 14/SC/0088]
653 and from the Medicines and Healthcare products Regulatory Agency for Clinical Trial Authorisation
654 [EudraCT number: 2013-004708-20; ClinicalTrials.gov NCT02019784]. The studies were conducted in
655 compliance with the principles of the Declaration of Helsinki (1996), principles of Good Clinical
656 Practice, Research Governance Framework and where relevant, the Medicines for Human Use
657 (Clinical Trial) Regulations. Clinical service users and caregivers were fully consulted and involved in
658 the design of both the study and the trial, and were given opportunities to review and feedback on
659 overall set-up, delivery and practical aspects, including input into development of all participant
660 facing documents. Only baseline pre-intervention data from the clinical trial participants are used in
661 this manuscript. Fully informed consent was obtained from all participants. Some participants eligible
662 for this study were unable to provide informed consent due to cognitive impairment arising from HE
663 and permission from a legal representative was sought.

664 Patient participants, or their legal representative in the case of incapacitation of a potential
665 participant, provided written informed consent within 48 hours of presentation. Patients were
666 managed according to standard evidence-based protocols and guidelines (European Association for
667 the Study of the Liver., 2018). Patient and Public Involvement and Engagement was undertaken with
668 a patient advisory group to determine acceptability of the studies, provided their perspective on
669 study design, informational material, measures to minimise participation burden and agreeing on a
670 dissemination plan of the findings.

671 Patient participants were stratified into and phenotyped according to clinically relevant groups based
672 on the severity and time course of their underlying cirrhosis, degree of stability and hepatic
673 decompensation, and presence and extent of hepatic and extra-hepatic organ failure at the time of

674 sampling. These groups were stable cirrhosis, acutely decompensated cirrhosis (AD) and acute-on-
675 chronic liver failure (ACLF), with a separately recruited healthy participant control cohort. AD was
676 defined by the acute development of 1 or more major complications of cirrhosis, including ascites,
677 hepatic encephalopathy, variceal haemorrhage, and bacterial infection. ACLF was defined and graded
678 according to the number of organ failures in concordance with criteria reported in the CANONIC study
679 (Arroyo et al., 2016; Moreau et al., 2013).

680 Demographic, clinical, and biochemical metadata were collected at the time of biological sampling.
681 Standard clinical composite scores used for risk stratification and prognostication included the Child-
682 Pugh score (Pugh et al., 1973), model for end-stage liver disease (MELD) (Kim et al., 2008), United
683 Kingdom model for end-stage liver disease (UKELD) (Asrani and Kim, 2010), and Chronic Liver Failure
684 Consortium-acute decompensation (CLIF-C AD) (Jalan et al., 2015). Healthy controls aged >18 years
685 (n = 40) were recruited to establish reference values for the various assays performed. Exclusion
686 criteria for healthy controls were body mass index <18 or >27; pregnancy or active breastfeeding, a
687 personal history of thrombotic or liver disease; chronic medical conditions requiring regular primary
688 or secondary care review and/or prescribed pharmacotherapies; or current use of anticoagulants,
689 platelet function inhibitors, or oral contraceptives, and no exposure to antibiotics in the previous 6
690 months.

691 **Faecal, urine and blood sample collection and preparation**

692 Plasma samples for bile acid and cytokine profiling were obtained within 24 hours of admission to
693 hospital. Blood was drawn into ethylenediaminetetraacetic acid (EDTA) containing vacuum tubes (BD
694 Vacutainer, Franklin Lakes, NJ, USA). Plasma fractions were collected from these tubes following
695 incubation at room temperature and centrifugation at 2,000 x g for 10 minutes at 4°C. Plasma aliquots
696 were stored immediately at -80°C until further analysis. Whole blood from EDTA tubes was aliquoted
697 into sterile microtubes for and stored immediately at -80°C for bacterial DNA quantification.

698 Faecal samples for 16S rRNA sequencing and calprotectin quantification were obtained within 48
699 hours of admission to hospital using non-treated sterile universal tubes. Faecal samples were kept at
700 4°C without any preservative and within 6 hours were aliquoted into 1 gram vials for storage at -80°C.
701 Serum and urine samples were prepared for NMR analyses using standardised protocols (Dona et al.,
702 2014).

703 **Isolation and quality assessment of faecal bacterial DNA**

704 Bacterial DNA was isolated from all faecal samples obtained. This was performed utilising an ISOLATE
705 II Faecal DNA Kit (Bioline, London, UK; BIO-52082). Faecal samples were thawed from -80°C at room
706 temperature for up to 30 minutes. 150mg of faecal material (crude faecal from each faecal sample)
707 was added directly to a Bashing Beads Lysis Tube (Zymo Research, Orange County, California, USA)
708 and rapidly lysed by bead beating in a vortex, without the use of organic denaturants or proteinases.
709 The DNA was then bound, isolated and purified using spin columns. To optimise the DNA binding
710 step, β -mercaptoethanol (Sigma-Aldrich, Saint Louis, Missouri, USA) was added to eliminate
711 deoxyribonucleases released during cell lysis, by reducing the disulfide bonds within the
712 deoxyribonuclease enzymes. This prevents enzymatic digestion of the DNA during its extraction
713 procedure, increasing the overall yield. The eluted DNA, free of contaminants and enzyme inhibitors,
714 is then used for downstream molecular biology applications including genotyping and sequencing.
715 Extracted DNA concentration and purity were measured using a NanoDrop spectrophotometer
716 (Thermo Fisher Scientific, Australia). Samples with DNA concentrations below the dynamic range of
717 the NanoDrop spectrophotometer were analysed using Qubit High-Sensitivity (HS) dsDNA Assay kit
718 (Life Technologies, Australia).

719 **Faecal 16S rRNA gene amplicon library preparation and sequencing**

720 Amplicons were generated using the method as described previously (Jervis-Bardy et al. 2015). Full
721 details of the library preparation and sequencing protocol are provided in Appendix section 9.3. In
722 brief, barcoded amplicon libraries for the bacterial community analysis on the Illumina MiSeq

723 platform were generated using degenerate primers targeting the V1 and V3 hypervariable regions of
724 the bacterial 16S rRNA gene and Nextera XT index kit (Illumina, Inc., Victoria, Australia).

725 Amplicons were generated using fusion degenerate primers 27 F (5'-
726 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGRGTGGCTCAG-3') and 519R (5'-
727 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTNTTACNGCGGCKGCTG-3') with ligated overhang
728 Illumina adapter consensus sequences in italic text. In brief, the initial PCR reactions were performed
729 on a Veriti 96-well Thermal Cycler (Life Technologies, Australia). The PCR reactions were performed
730 in the following programme: initiation enzyme activation at 95°C for 3 min, followed by 25 cycles
731 consisting of denaturation at 95°C for 30 sec, annealing at 55°C for 30 sec and extension at 72°C for
732 30 sec. After 25 cycles, the reaction was completed with a final extension of 7 min at 72°C.

733 The Illumina Nextera XT Index kit (Illumina Inc., San Diego, CA, USA) with dual 8-base indices were
734 used to allow for multiplexing. Two unique indices located on either end of the amplicon were chosen
735 based on the Nextera dual-indexing strategy. To incorporate the indices to the 16S amplicons, PCR
736 reactions were performed on a Veriti 96-well Thermal Cycler (Life Technologies, Australia). Cycling
737 conditions consisted of one cycle of 95°C for 3 min, followed by eight cycles of 95°C for 30 sec, 55°C
738 for 30 sec and 72°C for 30 sec, followed by a final extension cycle of 72°C for 5 min.

739 Prior to library pooling, the barcoded libraries were quantified using the Qubit dsDNA HS Assay Kit
740 (Life Technologies, Carlsbad, CA, USA). Results from this quantification step (amplicon concentration)
741 were used in downstream processing to eliminate contamination. The libraries were sequenced by 2
742 × 300 bp paired-end sequencing on the MiSeq platform using MiSeq v3 Reagent Kit (Illumina) at the
743 Flinders Genomics Facility, Adelaide, Australia. All sequence data generated have been submitted to
744 the Sequence Read Archive (Archive 2014).

745 **16S rRNA amplicon sequencing analysis**

746 The 16S rRNA amplicon sequencing raw reads are deposited in NCBI SRA under project
747 PRJNA1223169. Sequencing reads were analysed using OTU clustering approach via QIIME v1.9.1 as

748 previously described (Kiu et al., 2019). Briefly, raw paired-end reads were firstly merged using PEAR
749 v0.9.6 with -q 30 option (Zhang et al., 2014). Next, quality filtering is performed with
750 split_libraries_fastq.py (QIIME) with -q 29 to retain high-quality reads (Caporaso et al., 2010).
751 Subsequently, chimera removal was performed via chimera identification
752 (identify_chimeric_seqs.py) and chimera sequence removal script (filter_fasta.py). OTU clustering
753 was run via open reference approach (pick_open_reference_otus.py) which does not discard
754 unassigned reads, based on SILVA_132 16S rRNA database optimised for use with QIIME (Quast et
755 al., 2013). BIOM outputs of taxonomic profiles generated from QIIME were then exported using
756 MEGAN v6 (Huson et al., 2016).

757 The sequencing output of 135 samples included one sample containing only 405 sequences and this
758 was discarded from further analysis. The remaining 134 samples contained a mean of 13,905
759 sequences per sample (Standard Deviation 6,497) with a minimum of 2,761 and maximum of 38,637
760 sequences per sample. Rarefaction curves were generated using the rarecurve function in the vegan
761 package (Oksanen, 2017) in R to confirm acceptable levels of sequencing depth. Raw data was
762 normalised using the Deseq2 (Love et al., 2014) package in R using the
763 varianceStabilizingTransformation function.

764 ***Enterococcus* isolation, genomic DNA extraction, Whole Genome Sequencing (WGS) and analysis**

765 Selected faecal samples (~20mg) were subject to serial dilutions in sterile PBS before spread-plating
766 on Slanetz and Bartley agar (Thermo Scientific) for selection of *Enterococcus* colonies (Slanetz and
767 Bartley, 1957). Subsequently, distinct deep-red coloured colonies, presumably *Enterococci*, on the
768 agar plates were picked and re-streaked once on fresh Slanetz and Bartley agar after incubation at
769 40°C for 24h. Re-streaked agar plates were then incubated at 40°C for a further 24h to ensure isolate
770 purity prior to overnight culturing in 10ml Brain Heart Infusion media at 40°C to generate sizable
771 bacterial pellets for subsequent genomic DNA extraction. Genomic DNA extraction on the

772 Enterococcus isolates was performed using FastDNA Spin Kit for Soil (MP Biomedicals) as per
773 manufacturer's instructions as described previously (Gooch et al., 2021).

774 Sequencing library was prepared via a modified Illumina Nextera Flex low input tagmentation
775 approach as described previously (Baker et al., 2021; Gooch et al., 2021). Genomic DNA samples were
776 sequenced on Illumina NextSeq 500 with read lengths of 150bp (paired-end).

777 Sequencing reads were quality-filtered and adapter-removed using fastp v0.20.0 with -q 20 option
778 (Chen et al., 2018). Next, short reads were assembled using Unicycler v0.4.9 via primary de novo
779 assembler SPAdes v3.11.1 prior to read polishing via Pilon v1.22. Contigs of length <500 bp were then
780 removed from all draft genome assemblies (Bankevich et al., 2012; Walker et al., 2014; Wick et al.,
781 2017). Taxonomic assignment (Enterococcus faecium) to novel draft genome assemblies were
782 performed using GTDB-Tk v1.5.1 (Chaumeil et al., 2020).

783 A total of 185 *E. faecium* complete genome assemblies were retrieved from NCBI Genome database
784 (December 2021) for comparison purposes. Together with 5 novel *E. faecium* genomes (n=200), a
785 core gene alignment was generated using Panaroo v1.2.8 with --merge_paralogs option while SNP
786 variants were next extracted by snp-sites v2.3.3 (Page et al., 2016; Tonkin-Hill et al., 2020).
787 Subsequently, a phylogenetic tree was reconstructed via FastTree v2.1 -gtr (-nt) model based on the
788 alignment of core genome SNPs and visualised on iTOL v6 (Letunic and Bork, 2019; Price et al., 2009).

789 Gene search was performed via ABRicate v1.0.1 with --mincov=90 and--minid=90, using databases
790 ARG-ANNOT v6 (AMR genes) and VFDB (Virulence genes) (Gupta et al., 2014; Liu et al., 2019).
791 Nucleotide sequences of bile-salt resistance genes bsh (Accession: AY260046.1) and gltK (Accession:
792 EFF34375.1) were retrieved from GenBank (Benson et al., 2018).

793 **Faecal calprotectin quantification**

794 Faecal calprotectin was measured from frozen faecal samples using a commercially available enzyme-
795 linked immunosorbent assay (Bühlmann Laboratories AG, Schönenbuch, Switzerland) that measures
796 calprotectin in a quantitative manner. This was undertaken in a conventional hospital clinical

797 laboratory (ISO 15189 accredited) with regular interval review of standard operating procedures and
798 equipment calibration. Extraction buffer was added to aliquots of 50mg raw faeces at a
799 weight/volume ratio of 1:50 and homogenised by vortexing for 30 minutes. 2mL of the homogenate
800 was then centrifuged in a microcentrifuge for 5 min at 3000 g. Following centrifugation, the
801 calprotectin ELISA was performed using an automated Grifols Triturus® platform. The ELISA plate is
802 coated with a monoclonal capture antibody highly specific to the calprotectin heterodimeric and
803 polymeric complexes. After incubation, washing, a second incubation with a specific detection
804 antibody, and a further washing step, tetramethylbenzidine (blue colour formation) followed by a
805 stop solution (change to yellow colour) are added by the Triturus. The absorption was determined at
806 an optical density of 450 nm. The linear range of the test was 10-600 µg calprotectin/g faeces with
807 concentration-dependent intra- and inter-assay coefficients of between 2-5% and 4-8%, respectively.

808 **Whole blood 16S ribosomal DNA quantification**

809 The method for quantifying whole blood 16S ribosomal DNA has been previously published in detail
810 (Vergis et al., 2017). Prior to 16S rRNA gene PCR analysis, frozen whole blood samples were thawed
811 to room temperature over a 15-minute period. Mutanolysin (Sigma, St. Louis, Missouri, USA) was
812 added directly to the whole-blood sample; 10µL of 10U/µL enzyme was added for every 200µL of
813 blood being processed, and the sample was incubated for 30 minutes at 37°C.

814 DNA isolation was performed using a total whole blood volume of 200µL per sample. 19µL of
815 10mg/ml lysozyme and 1µL glycogen (Thermo Fisher Scientific; R0561), the latter to aid precipitation,
816 was added to the sample and placed in a water bath at 37°C for 30 minutes. A modified protocol from
817 the QIAamp DNA Blood Mini Kit (Qiagen, Inc., Valencia, CA) was then followed: 200µL of AL buffer was
818 added and the sample vortexed. 20µL of Proteinase K (Thermo Fisher Scientific; EO0491) was then
819 added and then incubated at 56°C for 1 hour in a heat block. After incubation, 200µL of 100% ethanol
820 was added and the resulting lysates were loaded onto the QIAamp DNA Mini kit spin columns.

821 The columns were then centrifuged at 6,000 x g for one minute, and 500µL wash buffer AW1 added,
822 again centrifuged at 6,000 x g for one minute. 500µL wash buffer AW2 was then added, centrifuged

823 at 13,000 x g for three minutes. 50µL of pre-warmed AE elution buffer was added with 5 minutes
824 waiting time, then centrifuged at 13,000 x g for one minute to obtain the DNA extracts. To maximise
825 extraction, the eluate was reapplied to the spin column and centrifuged at 6,000 x g for one minute.
826 PBS and healthy control whole blood PCR were included to quality check for contamination from the
827 process.

828 Real-time polymerase chain reaction (PCR) was used to assess the quantity of bacterial DNA by
829 comparing to known standards. The primers and TaqMan probes were the well-characterized RW01
830 and DG74 primers and TaqMan RDR245 universal probe (synthesized at Applied Biosystems, Foster
831 City, CA) and have been described previously (Jordan and Durso, 2005) with a 380bp 16S rRNA gene
832 target. This target is located in the highly conserved region of 16S bacterial rRNA gene in order to
833 detect the majority of bacterial species found in clinical samples.

834 The forward primer sequence was: 5'-AAC TGG AGG AAG GTG GGG AT3' and the reverse primer
835 sequence was 5'-AGG AGG TGA TCC AAC CGC A-3'. The TaqMan probe sequence was 5'-(6-FAM)-TA
836 CAA GGC CCG GGA ACG TAT TCA CCG-(TAMRA)-3'. Each well contained 5.5µL sterile water (UV
837 irradiated), 1µL RW01 forward primer (10uM), 1µL DG74 reverse primer (10µM), 0.5ul RDR245
838 TaqMan probe (10µM), 10µL of TaqMan Gene Expression Master Mix (Invitrogen; 4369016) and 2µL
839 of sample containing the DNA eluate.

840 A 96 well plate was used and each sample was run in triplicate, and for each plate that was run blank
841 wells were included, a negative control (sterile PBS) and various healthy control samples spiked with
842 a known quantity of E.coli and then serially diluted to generate a standard curve to allow absolute
843 quantification to be calculated. Accordingly, for each PCR run, a standard curve was generated by
844 including a healthy control blood sample which was spiked with known quantities of E.coli (0.4ng,
845 0.04ng, 0.004ng, 0.0004ng, 0.00004ng) using serial 10-fold dilutions and a negative control, also all
846 run in triplicate, and were put through the same DNA extraction process. Any sample displaying a
847 positive signal at or below the level of the negative control was considered negative. Any triplicate

848 group with readings >1 copy cycle apart was considered unreliable and discarded; otherwise, the
849 mean reading was calculated.

850 A StepOnePlus PCR instrument (Invitrogen) was used for real-time PCR, with an initial 2 minutes at
851 50°C and 10-minute denaturation at 95°C, followed by 40 cycles of 15 seconds at 95°C, 30 seconds at
852 60C (annealing) and 1 minute at 72°C (extension). Fluorescence measurements on the PCR
853 instrument were collected during the extension phase of each cycle, and a cycle threshold (C_T) value
854 for each sample and control (including a blank well) was calculated by determining the point at which
855 the fluorescence exceeded the threshold limit, which was set automatically. These values were
856 compared with the *E. coli* standards to obtain a relative quantification of bacterial DNA detected in
857 the whole blood and control samples. Standard curves were generated, and concentrations
858 interpolated in Prism, version 7.0 (GraphPad, La Jolla, CA, USA) The results were extrapolated to
859 picograms of bacterial DNA per millilitre of whole blood.

860 **Plasma cytokine analyses**

861 Plasma cytokines were measured as follows: IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 p70, IL-13, IFN- γ , IL1 β
862 and TNF- α using an electro-chemiluminescence platform (Meso Scale Discovery (MSD)). Samples
863 were run in duplicate on U-PLEX Proinflam Combo 1 Human™ plates (Cat# K15049K-1, MSD,
864 Gaithersburg, MD). This was conducted according to the manufacturer's protocol. The plate was
865 immediately read on a SECTOR(r) Imager (MSD, Gaithersburg, MD).

866 **Plasma bile acid profiling**

867 Bile acid (BA) profiling was done using an in-house high performance liquid chromatography tandem
868 mass spectrometry (LC-MS/MS) assay modified from published methodology (Tagliacozzi et al.,
869 2003). The method uses an Acentis fusedcore C18 analytical column (15064.6 mm, particle size 2.7
870 mm, Sigma-Aldrich) on a Jasco LC2000 series HPLC system attached to an API 3200 triple quadrupole
871 mass spectrometer (Applied Biosystems, Cheshire, UK). Mobile phases comprised (A) methanol or
872 (B) deionised H₂O, each containing 5 mM ammonium acetate (w/v) and 0.012% formic acid (v/v).

873 Negative ion mass spectra of the fractionated BAs were recorded in multiple reaction-monitoring
874 mode. Data were captured using Analyst Software version 1.4.2 (Applied Biosystems) and
875 quantitation carried out by peak area analysis corrected to internal standards (a2,2,4,4,d4-
876 deoxycholic acid for each of the bile acid chemistries; unconjugated, glycine- and taurine-
877 conjugated). The method was linear between 0.1 and 10 mmol/L for all BAs and their conjugates with
878 coefficients of variation (CV %) of 1.5–6.8% at the lower limit of quantitation (0.1 mmol/L). The inter-
879 assay CV was 3.6–8.0%.

880 **Plasma ¹H NMR spectroscopy**

881 All plasma samples were prepared according to the previously published papers by Dona et al. and
882 Trovato et al. (Dona et al., 2014; Trovato et al., 2021)[TOO ADD]. ¹H NMR spectra were acquired on
883 a Bruker 600 MHz (Avance III) spectrometer, operating at a ¹H frequency of 600.16 MHz (14.1 Tesla)
884 at 300K using a 5 mm BBI probe and an automated Sample Jet system (Bruker Biospin, Rheinstetten,
885 Germany). Full explanation of processing is given in the Supplementary section.

886 **Urine ¹H NMR spectroscopy**

887 Urinary NMR data were acquired at the Centre for Biomolecular Spectroscopy, King's College London,
888 using a Bruker 600-MHz (AVANCE NEO) NMR spectrometer with a ¹H/¹³C/¹⁵N TCI Prodigy (nitrogen-
889 cooled) probe (Bruker, Billerica, USA) as previously described (Bajaj et al., 2019). Pulse-collect NMR
890 data sets were acquired using PURGE water suppression (Le Guennec et al., 2017) and J-resolved
891 NMR sequences. Signal intensities of metabolite regions were obtained using intellibucketing within
892 Wiley KnowItAll® Informatics, Metabolomics Edition v17.0, Wiley Science Solutions, Colorado, USA.
893 NMR spectral regions excluded from the analysis at the outset were 10.0 ppm and 4.5-5.0 ppm
894 (residual water region). Selected intellibucket regions were manually adjusted to incorporate specific
895 metabolite peaks. The binned NMR spectral data outputted from Wiley KnowItAll® Informatics
896 Metabolomics Edition v17.0 were also analysed using MetaboAnalyst v4.0 program (J et al., 2018)
897 and exported to the Quadram Institute. Details can be found in the Supplementary section.

898 **Monocyte intracellular cytokine staining**

899 Monocyte intracellular cytokine staining was undertaken using thawed PBMCs from patients with
900 liver disease and at a density of 0.5 millions cells per ml. Cells were either stimulated with TLR2
901 (Pam3CSK4 5ug/ml), Invivogen, France), TLR4 (LPS 100 ng/ml), or TLR9 (CpG 10ug/ml) (Invivogen,
902 France) for 4 hours, or left unstimulated. Monocytes were identified using monoclonal antibodies for
903 surface markers: CD14 PE-Cy7, CD16 APC-H7 (BD Biosciences, UK) and HLA-DR PerCP (ThermoFisher
904 Scientific, UK). Intracellular cytokines were measured using protein transport inhibitor containing
905 monensin, permeabilization/fixation buffer and monoclonal antibodies TNF- α APC and IL-6 PE (BD
906 Biosciences, UK). Percentage positivity in CD14+ monocytes compared with isotype controls (APC
907 mouse IgG1; PE rat IgG2a) were assessed by flow cytometry as previously described (Antoniades et
908 al., 2014). The gating strategy that was employed is shown in Supplementary Figure 1.

909 **Statistical and bioinformatic analyses**

910 For microbiota diversity analysis the number of genera in each sample and the Inverse Simpson
911 diversity was calculated using the specnumber and the diversity functions on genus level taxonomic
912 sequence data in the vegan package (version 2.6-4) in R using raw sequence count data (Oksanen,
913 2017). Differences in alpha-diversity between cirrhosis severity and HC groups was tested with an
914 ANOVA using the aov function in R. Post-hoc pairwise comparisons were determined using the
915 TukeyHSD function in R.

916 To visualise clustering of gut bacterial communities between participants non-metric
917 multidimensional scaling (NMDS) based on a Bray-Curtis distance matrix and using the metaMDS
918 function with k = 3 dimensions contained within the vegan package (version 2.6-4) (Oksanen, 2017).
919 The influence of cirrhosis severity group compared to HC on participant microbiota clustering was
920 tested using a PERMANOVA test using the adonis2 function in the vegan package (version 2.6-4) with
921 a total of 10,000 permutations. Pairwise comparison of clustering of the three cirrhosis severity and
922 HC groups was compared using the pairwiseAdonis function in the pairwiseAdonis package (Martinez
923 Arbizu, 2020).

924 To explore the effect size and significance of associations between clinical metadata variables and
925 beta-diversity of the microbiota within patient samples the envfit function in the vegan package was
926 used to test associations of clinical metadata variables on NMDS ordination calculated using Bray-
927 Curtis dissimilarity after 10,000 permutations. In total, 76 clinical metadata variables were included
928 in the envfit analysis to explore their associations with the gut microbiota composition with three
929 samples excluded during analysis due to missing data (Supplementary File 2). The P-values for
930 combined continuous and factor variables were corrected for multiple comparisons using an FDR
931 adjustment (Benjamini–Hochberg procedure). For visualisation the R² for the forty significant
932 variables were presented as a bar plot while an arbitrary top ten clinical variables explaining the
933 highest amount of variance (R²) were plotted as an overlay on a NMDS plot of the individual gut
934 microbiota data using the ggplot2 package.

935 Associations between the relative abundance of individual bacterial genera and individual clinical
936 metadata variables were tested using the MaAsLin2 package (Mallick et al., 2021). For genus
937 abundance analysis MaAsLin2 was run with default parameters including multiple testing correction
938 using Benjamini-Hochberg FDR with a significance threshold on adjusted P-values of 0.25 as
939 recommended by the developers. Exceptions to default parameters included an applied minimum
940 prevalence of 0.01 and abundance cut-off of 0.01. Each metadata variable was tested individually.
941 For genus differential abundance analysis cirrhosis severity was included at a Fixed Effect with the
942 HC group as the reference group. For genus differential abundance analysis using antibiotic use, oral
943 food intake, and lactulose use each variable was tested individually. Positive associations were
944 identified antibiotic use, oral food intake, and lactulose and these three variables were combined
945 and tested together as Fixed Effects in a multivariable analysis for the final analysis.

946 Differential analysis of bile acid concentrations was performed using MaAsLin2 with multiple testing
947 correction using Benjamini-Hochberg FDR with a significance threshold on adjusted P-values of 0.25
948 as recommended by the developers. Exceptions to default parameters included no minimum
949 concentration nor abundance cut-off, CLR as the normalisation method and no transformation used.
950 Differential analysis of urinary metabolite and plasma concentrations were analysed using MaAsLin2

951 run with default parameters including multiple testing correction using Benjamini-Hochberg FDR with
952 a significance threshold on adjusted P-values of 0.25 as recommended by the developers. Exceptions
953 to default parameters included no minimum concentration nor abundance cut-off, and no
954 normalisation nor transformation used. The BestNormalize package (version 1.9.1.9000) (Peterson,
955 2021; Peterson and Cavanaugh, 2020) in R was used to optimally normalise each metabolite
956 individually before analysis using the bestnorm function. The method used to transform each variable
957 included in (Supplementary Table 3).

958 For correlation analysis the variables were normalised using the bestnorm function from the
959 bestNormalize package (version 1.9.1.9000). The method used to transform each variable included
960 in (Supplementary Table 4). Pearson correlations were used with statistical significance corrected for
961 multiple testing across genus tested using the False Discovery Rate method.

962

963

964

965

966 8. References

- 967 Abdugheni, R., Wang, W.-Z., Wang, Y.-J., Du, M.-X., Liu, F.-L., Zhou, N., Jiang, C.-Y., Wang, C.-Y., Wu,
968 L., Ma, J., Liu, C., Liu, S.-J., 2022. Metabolite profiling of human-originated Lachnospiraceae at
969 the strain level. *iMeta* 1, e58. <https://doi.org/10.1002/imt2.58>
- 970 Acharya, C., Bajaj, J.S., 2019. Altered Microbiome in Patients With Cirrhosis and Complications. *Clin*
971 *Gastroenterol Hepatol* 17, 307–321. <https://doi.org/10.1016/j.cgh.2018.08.008>
- 972 Adak, A., Khan, M.R., 2019. An insight into gut microbiota and its functionalities. *Cell Mol Life Sci* 76,
973 473–493. <https://doi.org/10.1007/s00018-018-2943-4>
- 974 Albillos, A., de Gottardi, A., Rescigno, M., 2020. The gut-liver axis in liver disease: Pathophysiological
975 basis for therapy. *J Hepatol* 72, 558–577. <https://doi.org/10.1016/j.jhep.2019.10.003>
- 976 Albillos, A., Martin-Mateos, R., Van der Merwe, S., Wiest, R., Jalan, R., Álvarez-Mon, M., 2022.
977 Cirrhosis-associated immune dysfunction. *Nat Rev Gastroenterol Hepatol* 19, 112–134.
978 <https://doi.org/10.1038/s41575-021-00520-7>
- 979 Alexopoulou, A., Agiasotelli, D., Vasilieva, L.E., Dourakis, S.P., 2017. Bacterial translocation markers
980 in liver cirrhosis. *Ann Gastroenterol* 30, 486–497. <https://doi.org/10.20524/aog.2017.0178>
- 981 Antoniadis, C.G., Khamri, W., Abeles, R.D., Taams, L.S., Triantafyllou, E., Possamai, L.A., Bernsmeier,
982 C., Mitry, R.R., O'Brien, A., Gilroy, D., Goldin, R., Heneghan, M., Heaton, N., Jassem, W., Bernal,
983 W., Vergani, D., Ma, Y., Quaglia, A., Wendon, J., Thursz, M., 2014. Secretory leukocyte
984 protease inhibitor: a pivotal mediator of anti-inflammatory responses in acetaminophen-
985 induced acute liver failure. *Hepatology* 59, 1564–1576. <https://doi.org/10.1002/hep.26933>
- 986 Arroyo, V., Moreau, R., Jalan, R., Ginès, P., EASL-CLIF Consortium CANONIC Study, 2015. Acute-on-
987 chronic liver failure: A new syndrome that will re-classify cirrhosis. *J Hepatol* 62, S131-143.
988 <https://doi.org/10.1016/j.jhep.2014.11.045>
- 989 Arroyo, V., Moreau, R., Kamath, P.S., Jalan, R., Ginès, P., Nevens, F., Fernández, J., To, U., García-Tsao,
990 G., Schnabl, B., 2016. Acute-on-chronic liver failure in cirrhosis. *Nat Rev Dis Primers* 2, 16041.
991 <https://doi.org/10.1038/nrdp.2016.41>
- 992 Asrani, S.K., Kim, W.R., 2010. Organ allocation for chronic liver disease: model for end-stage liver
993 disease and beyond. *Curr Opin Gastroenterol* 26, 209–213.
994 <https://doi.org/10.1097/MOG.0b013e32833867d8>
- 995 Bach Knudsen, K.E., Lærke, H.N., Hedemann, M.S., Nielsen, T.S., Ingerslev, A.K., Gundelund Nielsen,
996 D.S., Theil, P.K., Purup, S., Hald, S., Schioldan, A.G., Marco, M.L., Gregersen, S., Hermansen,
997 K., 2018. Impact of Diet-Modulated Butyrate Production on Intestinal Barrier Function and
998 Inflammation. *Nutrients* 10, 1499. <https://doi.org/10.3390/nu10101499>
- 999 Bajaj, J.S., Heuman, D.M., Hylemon, P.B., Sanyal, A.J., White, M.B., Monteith, P., Noble, N.A., Unser,
1000 A.B., Daita, K., Fisher, A.R., Sikaroodi, M., Gillevet, P.M., 2014. Altered profile of human gut
1001 microbiome is associated with cirrhosis and its complications. *Journal of Hepatology* 60, 940–
1002 947. <https://doi.org/10.1016/j.jhep.2013.12.019>
- 1003 Bajaj, J.S., Reddy, K.R., Tandon, P., Garcia-Tsao, G., Kamath, P.S., O'Leary, J.G., Wong, F., Lai, J., Vargas,
1004 H., Thuluvath, P.J., Subramanian, R.M., Pena-Rodriguez, M., Sikaroodi, M., Thacker, L.R.,

- 1005 Gillevet, P.M., 2022. Association of serum metabolites and gut microbiota at hospital
1006 admission with nosocomial infection development in patients with cirrhosis. *Liver Transpl* 28,
1007 1831–1840. <https://doi.org/10.1002/lt.26552>
- 1008 Bajaj, J.S., Ridlon, J.M., Hylemon, P.B., Thacker, L.R., Heuman, D.M., Smith, S., Sikaroodi, M., Gillevet,
1009 P.M., 2012. Linkage of gut microbiome with cognition in hepatic encephalopathy. *Am J Physiol*
1010 *Gastrointest Liver Physiol* 302, G168-175. <https://doi.org/10.1152/ajpgi.00190.2011>
- 1011 Bajaj, J.S., Salzman, N., Acharya, C., Takei, H., Kakiyama, G., Fagan, A., White, M.B., Gavis, E.A., Holtz,
1012 M.L., Hayward, M., Nittono, H., Hylemon, P.B., Cox, I.J., Williams, R., Taylor-Robinson, S.D.,
1013 Sterling, R.K., Matherly, S.C., Fuchs, M., Lee, H., Puri, P., Stravitz, R.T., Sanyal, A.J., Ajayi, L., Le
1014 Guennec, A., Atkinson, R.A., Siddiqui, M.S., Luketic, V., Pandak, W.M., Sikaroodi, M., Gillevet,
1015 P.M., 2019. Microbial functional change is linked with clinical outcomes after capsular fecal
1016 transplant in cirrhosis. *JCI Insight* 4, e133410, 133410.
1017 <https://doi.org/10.1172/jci.insight.133410>
- 1018 Baker, D.J., Aydin, A., Le-Viet, T., Kay, G.L., Rudder, S., de Oliveira Martins, L., Tedim, A.P., Kolyva, A.,
1019 Diaz, M., Alikhan, N.-F., Meadows, L., Bell, A., Gutierrez, A.V., Trotter, A.J., Thomson, N.M.,
1020 Gilroy, R., Griffith, L., Adriaenssens, E.M., Stanley, R., Charles, I.G., Elumogo, N., Wain, J.,
1021 Prakash, R., Meader, E., Mather, A.E., Webber, M.A., Dervisevic, S., Page, A.J., O’Grady, J.,
1022 2021. CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes. *Genome Medicine*
1023 13, 21. <https://doi.org/10.1186/s13073-021-00839-5>
- 1024 Bankevich, A., Nurk, S., Antipov, D., Gurevich, A.A., Dvorkin, M., Kulikov, A.S., Lesin, V.M., Nikolenko,
1025 S.I., Pham, S., Prjibelski, A.D., Pyshkin, A.V., Sirotkin, A.V., Vyahhi, N., Tesler, G., Alekseyev,
1026 M.A., Pevzner, P.A., 2012. SPAdes: a new genome assembly algorithm and its applications to
1027 single-cell sequencing. *J Comput Biol* 19, 455–477. <https://doi.org/10.1089/cmb.2012.0021>
- 1028 Benson, D.A., Cavanaugh, M., Clark, K., Karsch-Mizrachi, I., Ostell, J., Pruitt, K.D., Sayers, E.W., 2018.
1029 GenBank. *Nucleic Acids Research* 46, D41–D47. <https://doi.org/10.1093/nar/gkx1094>
- 1030 Caballero-Flores, G., Pickard, J.M., Núñez, G., 2023. Microbiota-mediated colonization resistance:
1031 mechanisms and regulation. *Nat Rev Microbiol* 21, 347–360. <https://doi.org/10.1038/s41579-022-00833-7>
- 1033 Caporaso, J.G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F.D., Costello, E.K., Fierer, N.,
1034 Peña, A.G., Goodrich, J.K., Gordon, J.I., Huttley, G.A., Kelley, S.T., Knights, D., Koenig, J.E., Ley,
1035 R.E., Lozupone, C.A., McDonald, D., Muegge, B.D., Pirrung, M., Reeder, J., Sevinsky, J.R.,
1036 Turnbaugh, P.J., Walters, W.A., Widmann, J., Yatsunencko, T., Zaneveld, J., Knight, R., 2010.
1037 QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* 7, 335–
1038 336. <https://doi.org/10.1038/nmeth.f.303>
- 1039 Chaumeil, P.-A., Mussig, A.J., Hugenholtz, P., Parks, D.H., 2020. GTDB-Tk: a toolkit to classify genomes
1040 with the Genome Taxonomy Database. *Bioinformatics* 36, 1925–1927.
1041 <https://doi.org/10.1093/bioinformatics/btz848>
- 1042 Chen, S., Zhou, Y., Chen, Y., Gu, J., 2018. fastp: an ultra-fast all-in-one FASTQ preprocessor.
1043 *Bioinformatics* 34, i884–i890. <https://doi.org/10.1093/bioinformatics/bty560>

- 1044 Cibulková, I., Řehořová, V., Hajer, J., Duška, F., 2021. Fecal Microbial Transplantation in Critically Ill
1045 Patients—Structured Review and Perspectives. *Biomolecules* 11, 1459.
1046 <https://doi.org/10.3390/biom11101459>
- 1047 Da Silva, H.E., Teterina, A., Comelli, E.M., Taibi, A., Arendt, B.M., Fischer, S.E., Lou, W., Allard, J.P.,
1048 2018. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass
1049 index and insulin resistance. *Sci Rep* 8, 1466. <https://doi.org/10.1038/s41598-018-19753-9>
- 1050 D’Amico, G., Bernardi, M., Angeli, P., 2022. Towards a new definition of decompensated cirrhosis.
1051 *Journal of Hepatology* 76, 202–207. <https://doi.org/10.1016/j.jhep.2021.06.018>
- 1052 Dona, A.C., Jiménez, B., Schäfer, H., Humpfer, E., Spraul, M., Lewis, M.R., Pearce, J.T.M., Holmes, E.,
1053 Lindon, J.C., Nicholson, J.K., 2014. Precision high-throughput proton NMR spectroscopy of
1054 human urine, serum, and plasma for large-scale metabolic phenotyping. *Anal Chem* 86, 9887–
1055 9894. <https://doi.org/10.1021/ac5025039>
- 1056 Dubinkina, V.B., Tyakht, A.V., Odintsova, V.Y., Yarygin, K.S., Kovarsky, B.A., Pavlenko, A.V., Ischenko,
1057 D.S., Popenko, A.S., Alexeev, D.G., Taraskina, A.Y., Nasyrova, R.F., Krupitsky, E.M., Shalikiani,
1058 N.V., Bakulin, I.G., Shcherbakov, P.L., Skorodumova, L.O., Larin, A.K., Kostyukova, E.S.,
1059 Abdulkhakov, R.A., Abdulkhakov, S.R., Malanin, S.Y., Ismagilova, R.K., Grigoryeva, T.V., Ilina,
1060 E.N., Govorun, V.M., 2017. Links of gut microbiota composition with alcohol dependence
1061 syndrome and alcoholic liver disease. *Microbiome* 5, 141. [https://doi.org/10.1186/s40168-](https://doi.org/10.1186/s40168-017-0359-2)
1062 [017-0359-2](https://doi.org/10.1186/s40168-017-0359-2)
- 1063 European Association for the Study of the Liver., 2018. EASL Clinical Practice Guidelines for the
1064 management of patients with decompensated cirrhosis. *J Hepatol* 69, 406–460.
1065 <https://doi.org/10.1016/j.jhep.2018.03.024>
- 1066 Fagan, K.J., Rogers, G.B., Melino, M., Arthur, D.M., Costello, M.-E., Morrison, M., Powell, E.E., Irvine,
1067 K.M., 2015. Ascites Bacterial Burden and Immune Cell Profile Are Associated with Poor Clinical
1068 Outcomes in the Absence of Overt Infection. *PLoS One* 10, e0120642.
1069 <https://doi.org/10.1371/journal.pone.0120642>
- 1070 Flint, H.J., Scott, K.P., Duncan, S.H., Louis, P., Forano, E., 2012. Microbial degradation of complex
1071 carbohydrates in the gut. *Gut Microbes* 3, 289–306. <https://doi.org/10.4161/gmic.19897>
- 1072 Garrett, W.S., 2020. Enterococcus in Graft-versus-Host Disease. *N Engl J Med* 382, 1064–1066.
1073 <https://doi.org/10.1056/NEJMcibr1915978>
- 1074 Gatarek, P., Kaluzna-Czaplinska, J., 2021. Trimethylamine N-oxide (TMAO) in human health. *EXCLI J*
1075 20, 301–319. <https://doi.org/10.17179/excli2020-3239>
- 1076 Ghosh, S., Whitley, C.S., Haribabu, B., Jala, V.R., 2021. Regulation of Intestinal Barrier Function by
1077 Microbial Metabolites. *Cellular and Molecular Gastroenterology and Hepatology* 11, 1463–
1078 1482. <https://doi.org/10.1016/j.jcmgh.2021.02.007>
- 1079 Gooch, H.C.C., Kiu, R., Rudder, S., Baker, D.J., Hall, L.J., Maxwell, A., 2021. *Enterococcus innesii* sp.
1080 nov., isolated from the wax moth *Galleria mellonella*. *Int J Syst Evol Microbiol* 71, 005168.
1081 <https://doi.org/10.1099/ijsem.0.005168>
- 1082 Gupta, S.K., Padmanabhan, B.R., Diene, S.M., Lopez-Rojas, R., Kempf, M., Landraud, L., Rolain, J.-M.,
1083 2014. ARG-ANNOT, a New Bioinformatic Tool To Discover Antibiotic Resistance Genes in

- 1084 Bacterial Genomes. *Antimicrob Agents Chemother* 58, 212–220.
1085 <https://doi.org/10.1128/AAC.01310-13>
- 1086 Hendrickx, A.P.A., van Luit-Asbroek, M., Schapendonk, C.M.E., van Wamel, W.J.B., Braat, J.C.,
1087 Wijnands, L.M., Bonten, M.J.M., Willems, R.J.L., 2009. SgrA, a nidogen-binding LPXTG surface
1088 adhesin implicated in biofilm formation, and EcbA, a collagen binding MSCRAMM, are two
1089 novel adhesins of hospital-acquired *Enterococcus faecium*. *Infect Immun* 77, 5097–5106.
1090 <https://doi.org/10.1128/IAI.00275-09>
- 1091 Hernaez, R., Solà, E., Moreau, R., Ginès, P., 2017. Acute-on-chronic liver failure: an update. *Gut* 66,
1092 541–553. <https://doi.org/10.1136/gutjnl-2016-312670>
- 1093 Horvatits, T., Drolz, A., Roedl, K., Rutter, K., Ferlitsch, A., Fauler, G., Trauner, M., Fuhrmann, V., 2017.
1094 Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in
1095 patients with non-cholestatic cirrhosis. *Liver Int* 37, 224–231.
1096 <https://doi.org/10.1111/liv.13201>
- 1097 Hsu, C.L., Schnabl, B., 2023. The gut–liver axis and gut microbiota in health and liver disease. *Nat Rev*
1098 *Microbiol* 21, 719–733. <https://doi.org/10.1038/s41579-023-00904-3>
- 1099 Huang, D.Q., Terrault, N.A., Tacke, F., Gluud, L.L., Arrese, M., Bugianesi, E., Loomba, R., 2023. Global
1100 epidemiology of cirrhosis — aetiology, trends and predictions. *Nat Rev Gastroenterol Hepatol*
1101 20, 388–398. <https://doi.org/10.1038/s41575-023-00759-2>
- 1102 Hufnagel, M., Liese, C., Loescher, C., Kunze, M., Proempeler, H., Berner, R., Krueger, M., 2007.
1103 Enterococcal colonization of infants in a neonatal intensive care unit: associated predictors,
1104 risk factors and seasonal patterns. *BMC Infect Dis* 7, 107. <https://doi.org/10.1186/1471-2334-7-107>
- 1106 Huson, D.H., Beier, S., Flade, I., Górska, A., El-Hadidi, M., Mitra, S., Ruscheweyh, H.-J., Tappu, R., 2016.
1107 MEGAN Community Edition - Interactive Exploration and Analysis of Large-Scale Microbiome
1108 Sequencing Data. *PLOS Computational Biology* 12, e1004957.
1109 <https://doi.org/10.1371/journal.pcbi.1004957>
- 1110 J, C., O, S., C, L., I, C., S, L., G, B., Ds, W., J, X., 2018. MetaboAnalyst 4.0: towards more transparent
1111 and integrative metabolomics analysis. *Nucleic acids research* 46.
1112 <https://doi.org/10.1093/nar/gky310>
- 1113 Jalan, R., Pavesi, M., Saliba, F., Amorós, A., Fernandez, J., Holland-Fischer, P., Sawhney, R., Mookerjee,
1114 R., Caraceni, P., Moreau, R., Ginès, P., Durand, F., Angeli, P., Alessandria, C., Laleman, W.,
1115 Trebicka, J., Samuel, D., Zeuzem, S., Gustot, T., Gerbes, A.L., Wendon, J., Bernardi, M., Arroyo,
1116 V., CANONIC Study Investigators; EASL-CLIF Consortium, 2015. The CLIF Consortium Acute
1117 Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without
1118 acute-on-chronic liver failure. *J Hepatol* 62, 831–840.
1119 <https://doi.org/10.1016/j.jhep.2014.11.012>
- 1120 Jin, M., Kalainy, S., Baskota, N., Chiang, D., Deehan, E.C., McDougall, C., Tandon, P., Martínez, I.,
1121 Cervera, C., Walter, J., Abraldes, J.G., 2019. Faecal microbiota from patients with cirrhosis has
1122 a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids. *Liver Int*
1123 39, 1437–1447. <https://doi.org/10.1111/liv.14106>

- 1124 Jordan, J.A., Durso, M.B., 2005. Real-time polymerase chain reaction for detecting bacterial DNA
1125 directly from blood of neonates being evaluated for sepsis. *J Mol Diagn* 7, 575–581.
1126 [https://doi.org/10.1016/S1525-1578\(10\)60590-9](https://doi.org/10.1016/S1525-1578(10)60590-9)
- 1127 Kakiyama, G., Muto, A., Takei, H., Nittono, H., Murai, T., Kurosawa, T., Hofmann, A.F., Pandak, W.M.,
1128 Bajaj, J.S., 2014. A simple and accurate HPLC method for fecal bile acid profile in healthy and
1129 cirrhotic subjects: validation by GC-MS and LC-MS. *J Lipid Res* 55, 978–990.
1130 <https://doi.org/10.1194/jlr.D047506>
- 1131 Kakiyama, G., Pandak, W.M., Gillevet, P.M., Hylemon, P.B., Heuman, D.M., Daita, K., Takei, H., Muto,
1132 A., Nittono, H., Ridlon, J.M., White, M.B., Noble, N.A., Monteith, P., Fuchs, M., Thacker, L.R.,
1133 Sikaroodi, M., Bajaj, J.S., 2013. Modulation of the fecal bile acid profile by gut microbiota in
1134 cirrhosis. *J Hepatol* 58, 949–955. <https://doi.org/10.1016/j.jhep.2013.01.003>
- 1135 Katoonizadeh, A., Laleman, W., Verslype, C., Wilmer, A., Maleux, G., Roskams, T., Nevens, F., 2010.
1136 Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. *Gut* 59,
1137 1561–1569. <https://doi.org/10.1136/gut.2009.189639>
- 1138 Kim, W.R., Biggins, S.W., Kremers, W.K., Wiesner, R.H., Kamath, P.S., Benson, J.T., Edwards, E.,
1139 Therneau, T.M., 2008. Hyponatremia and mortality among patients on the liver-transplant
1140 waiting list. *N Engl J Med* 359, 1018–1026. <https://doi.org/10.1056/NEJMoa0801209>
- 1141 Kiu, R., Brown, J., Bedwell, H., Leclaire, C., Caim, S., Pickard, D., Dougan, G., Dixon, R.A., Hall, L.J.,
1142 2019. Genomic analysis on broiler-associated *Clostridium perfringens* strains and exploratory
1143 caecal microbiome investigation reveals key factors linked to poultry necrotic enteritis.
1144 *Animal Microbiome* 1, 12. <https://doi.org/10.1186/s42523-019-0015-1>
- 1145 Le Guennec, A., Tayyari, F., Edison, A.S., 2017. Alternatives to Nuclear Overhauser Enhancement
1146 Spectroscopy Presat and Carr-Purcell-Meiboom-Gill Presat for NMR-Based Metabolomics.
1147 *Anal Chem* 89, 8582–8588. <https://doi.org/10.1021/acs.analchem.7b02354>
- 1148 Lee, S., Arefaine, B., Begum, N., Stamouli, M., Witherden, E., Mohamad, M., Harzandi, A., Zamalloa,
1149 A., Cai, H., Williams, R., Curtis, M., Edwards, L.A., Chokshi, S., Mardinoglu, A., Proctor, G.,
1150 Moyes, D., McPhail, M.J., Shawcross, D.L., Uhlen, M., Shoaie, S., Patel, V.C., 2024a. Oral-gut
1151 microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes
1152 and salivatypes, virulence factors and antimicrobial. *J Hepatol* S0168-8278(24)02635–7.
1153 <https://doi.org/10.1016/j.jhep.2024.09.046>
- 1154 Lee, S., Arefaine, B., Begum, N., Stamouli, M., Witherden, E., Mohamad, M., Harzandi, A., Zamalloa,
1155 A., Cai, H., Williams, R., Curtis, M.A., Edwards, L.A., Chokshi, S., Mardinoglu, A., Proctor, G.,
1156 Moyes, D.L., McPhail, M.J., Shawcross, D.L., Uhlen, M., Shoaie, S., Patel, V.C., 2024b. Oral-gut
1157 microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes
1158 and salivatypes, virulence factors and antimicrobial resistance. *Journal of Hepatology* 0.
1159 <https://doi.org/10.1016/j.jhep.2024.09.046>
- 1160 Lees, H.J., Swann, J.R., Wilson, I.D., Nicholson, J.K., Holmes, E., 2013. Hippurate: the natural history
1161 of a mammalian-microbial cometabolite. *J Proteome Res* 12, 1527–1546.
1162 <https://doi.org/10.1021/pr300900b>
- 1163 Letunic, I., Bork, P., 2019. Interactive Tree Of Life (iTOL) v4: recent updates and new developments.
1164 *Nucleic Acids Research* 47, W256–W259. <https://doi.org/10.1093/nar/gkz239>

- 1165 Liu, B., Zheng, D., Jin, Q., Chen, L., Yang, J., 2019. VFDB 2019: a comparative pathogenomic platform
1166 with an interactive web interface. *Nucleic Acids Research* 47, D687–D692.
1167 <https://doi.org/10.1093/nar/gky1080>
- 1168 Love, M.I., Huber, W., Anders, S., 2014. Moderated estimation of fold change and dispersion for RNA-
1169 seq data with DESeq2. *Genome Biol* 15, 550. <https://doi.org/10.1186/s13059-014-0550-8>
- 1170 Mallick, H., Rahnavard, A., McIver, L.J., Ma, S., Zhang, Y., Nguyen, L.H., Tickle, T.L., Weingart, G., Ren,
1171 B., Schwager, E.H., Chatterjee, S., Thompson, K.N., Wilkinson, J.E., Subramanian, A., Lu, Y.,
1172 Waldron, L., Paulson, J.N., Franzosa, E.A., Bravo, H.C., Huttenhower, C., 2021. Multivariable
1173 association discovery in population-scale meta-omics studies. *PLOS Computational Biology*
1174 17, e1009442. <https://doi.org/10.1371/journal.pcbi.1009442>
- 1175 Martinez Arbizu, P., 2020. pairwiseAdonis: Pairwise multilevel comparison using adonis.
- 1176 Moreau, R., Jalan, R., Gines, P., Pavesi, M., Angeli, P., Cordoba, J., Durand, F., Gustot, T., Saliba, F.,
1177 Domenicali, M., Gerbes, A., Wendon, J., Alessandria, C., Laleman, W., Zeuzem, S., Trebicka, J.,
1178 Bernardi, M., Arroyo, V., CANONIC Study Investigators of the EASL–CLIF Consortium, 2013.
1179 Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute
1180 decompensation of cirrhosis. *Gastroenterology* 144, 1426–1437, 1437.e1–9.
1181 <https://doi.org/10.1053/j.gastro.2013.02.042>
- 1182 Moubareck, C., Gavini, F., Vaugien, L., Butel, M.J., Doucet-Populaire, F., 2005. Antimicrobial
1183 susceptibility of bifidobacteria. *J Antimicrob Chemother* 55, 38–44.
1184 <https://doi.org/10.1093/jac/dkh495>
- 1185 Mouzaki, M., Wang, A.Y., Bandsma, R., Comelli, E.M., Arendt, B.M., Zhang, L., Fung, S., Fischer, S.E.,
1186 McGilvray, I.G., Allard, J.P., 2016. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.
1187 *PLoS One* 11, e0151829. <https://doi.org/10.1371/journal.pone.0151829>
- 1188 Nallapareddy, S.R., Singh, K.V., Okhuysen, P.C., Murray, B.E., 2008. A functional collagen adhesin
1189 gene, acm, in clinical isolates of *Enterococcus faecium* correlates with the recent success of
1190 this emerging nosocomial pathogen. *Infect Immun* 76, 4110–4119.
1191 <https://doi.org/10.1128/IAI.00375-08>
- 1192 Odenwald, M.A., Lin, H., Lehmann, C., Dylla, N.P., Cole, C.G., Mostad, J.D., Pappas, T.E., Ramaswamy,
1193 R., Moran, A., Hutchison, A.L., Stutz, M.R., Dela Cruz, M., Adler, E., Boissiere, J., Khalid, M.,
1194 Cantoral, J., Haro, F., Oliveira, R.A., Waligurski, E., Cotter, T.G., Light, S.H., Beavis, K.G.,
1195 Sundararajan, A., Sidebottom, A.M., Reddy, K.G., Paul, S., Pillai, A., Te, H.S., Rinella, M.E.,
1196 Charlton, M.R., Pamer, E.G., Aronsohn, A.I., 2023. Bifidobacteria metabolize lactulose to
1197 optimize gut metabolites and prevent systemic infection in patients with liver disease. *Nat*
1198 *Microbiol* 1–17. <https://doi.org/10.1038/s41564-023-01493-w>
- 1199 Oksanen, F., 2017. Vegan: Community Ecology Package.
- 1200 Organ, C.L., Li, Z., Sharp, T.E., Polhemus, D.J., Gupta, N., Goodchild, T.T., Tang, W.H.W., Hazen, S.L.,
1201 Lefer, D.J., 2020. Nonlethal Inhibition of Gut Microbial Trimethylamine N-oxide Production
1202 Improves Cardiac Function and Remodeling in a Murine Model of Heart Failure. *Journal of the*
1203 *American Heart Association* 9, e016223. <https://doi.org/10.1161/JAHA.119.016223>

- 1204 Page, A.J., Taylor, B., Delaney, A.J., Soares, J., Seemann, T., Keane, J.A., Harris, S.R., 2016. SNP-sites:
1205 rapid efficient extraction of SNPs from multi-FASTA alignments. *Microb Genom* 2, e000056.
1206 <https://doi.org/10.1099/mgen.0.000056>
- 1207 Pallister, T., Jackson, M.A., Martin, T.C., Zierer, J., Jennings, A., Mohny, R.P., MacGregor, A., Steves,
1208 C.J., Cassidy, A., Spector, T.D., Menni, C., 2017. Hippurate as a metabolomic marker of gut
1209 microbiome diversity: Modulation by diet and relationship to metabolic syndrome. *Sci Rep* 7,
1210 13670. <https://doi.org/10.1038/s41598-017-13722-4>
- 1211 Peterson, R.A., 2021. Finding Optimal Normalizing Transformations via bestNormalize. *The R Journal*
1212 13, 310–329.
- 1213 Peterson, R.A., Cavanaugh, J.E., 2020. Ordered quantile normalization: a semiparametric
1214 transformation built for the cross-validation era. *Journal of Applied Statistics* 47, 2312–2327.
1215 <https://doi.org/10.1080/02664763.2019.1630372>
- 1216 Piano, S., Singh, V., Caraceni, P., Maiwall, R., Alessandria, C., Fernandez, J., Soares, E.C., Kim, D.J., Kim,
1217 S.E., Marino, M., Vorobioff, J., Barea, R. de C.R., Merli, M., Elkrief, L., Vargas, V., Krag, A., Singh,
1218 S.P., Lesmana, L.A., Toledo, C., Marciano, S., Verhelst, X., Wong, F., Intagliata, N., Rabinowich,
1219 L., Colombato, L., Kim, S.G., Gerbes, A., Durand, F., Roblero, J.P., Bhamidimarri, K.R., Boyer,
1220 T.D., Maevskaya, M., Fassio, E., Kim, H.S., Hwang, J.S., Gines, P., Gadano, A., Sarin, S.K., Angeli,
1221 P., International Club of Ascites Global Study Group, 2019. Epidemiology and Effects of
1222 Bacterial Infections in Patients With Cirrhosis Worldwide. *Gastroenterology* 156, 1368-
1223 1380.e10. <https://doi.org/10.1053/j.gastro.2018.12.005>
- 1224 Price, M.N., Dehal, P.S., Arkin, A.P., 2009. FastTree: Computing Large Minimum Evolution Trees with
1225 Profiles instead of a Distance Matrix. *Molecular Biology and Evolution* 26, 1641–1650.
1226 <https://doi.org/10.1093/molbev/msp077>
- 1227 Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., Williams, R., 1973. Transection of the
1228 oesophagus for bleeding oesophageal varices. *Br J Surg* 60, 646–649.
1229 <https://doi.org/10.1002/bjs.1800600817>
- 1230 Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., Glöckner, F.O., 2013.
1231 The SILVA ribosomal RNA gene database project: improved data processing and web-based
1232 tools. *Nucleic Acids Research* 41, D590–D596. <https://doi.org/10.1093/nar/gks1219>
- 1233 Ridlon, J.M., Alves, J.M., Hylemon, P.B., Bajaj, J.S., 2013. Cirrhosis, bile acids and gut microbiota:
1234 unraveling a complex relationship. *Gut Microbes* 4, 382–387.
1235 <https://doi.org/10.4161/gmic.25723>
- 1236 Riva, A., Gray, E.H., Azarian, S., Zamalloa, A., McPhail, M.J.W., Vincent, R.P., Williams, R., Chokshi, S.,
1237 Patel, V.C., Edwards, L.A., 2020. Faecal cytokine profiling as a marker of intestinal
1238 inflammation in acutely decompensated cirrhosis. *JHEP Rep* 2, 100151.
1239 <https://doi.org/10.1016/j.jhepr.2020.100151>
- 1240 Seishima, J., Iida, N., Kitamura, K., Yutani, M., Wang, Z., Seki, A., Yamashita, Taro, Sakai, Y., Honda,
1241 M., Yamashita, Tatsuya, Kagaya, T., Shirota, Y., Fujinaga, Y., Mizukoshi, E., Kaneko, S., 2019.
1242 Gut-derived *Enterococcus faecium* from ulcerative colitis patients promotes colitis in a
1243 genetically susceptible mouse host. *Genome Biol* 20, 252. <https://doi.org/10.1186/s13059-019-1879-9>
1244

- 1245 Shah, N.J., Mousa, O.Y., Syed, K., John, S., 2024. Acute on Chronic Liver Failure, in: StatPearls.
1246 StatPearls Publishing, Treasure Island (FL).
- 1247 Slanetz, L.W., Bartley, C.H., 1957. NUMBERS OF ENTEROCOCCI IN WATER, SEWAGE, AND FECES
1248 DETERMINED BY THE MEMBRANE FILTER TECHNIQUE WITH AN IMPROVED MEDIUM1. J
1249 Bacteriol 74, 591–595.
- 1250 Solé, C., Guilly, S., Da Silva, K., Llopis, M., Le-Chatelier, E., Huelin, P., Carol, M., Moreira, R., Fabrellas,
1251 N., De Prada, G., Napoleone, L., Graupera, I., Pose, E., Juanola, A., Borrueal, N., Berland, M.,
1252 Toapanta, D., Casellas, F., Guarner, F., Doré, J., Solà, E., Ehrlich, S.D., Ginès, P., 2021.
1253 Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics:
1254 Relationship With Acute-on-Chronic Liver Failure and Prognosis. *Gastroenterology* 160, 206-
1255 218.e13. <https://doi.org/10.1053/j.gastro.2020.08.054>
- 1256 Tagliacozzi, D., Mozzi, A.F., Casetta, B., Bertucci, P., Bernardini, S., Di Ilio, C., Urbani, A., Federici, G.,
1257 2003. Quantitative analysis of bile acids in human plasma by liquid chromatography-
1258 electrospray tandem mass spectrometry: a simple and rapid one-step method. *Clin Chem Lab*
1259 *Med* 41, 1633–1641. <https://doi.org/10.1515/CCLM.2003.247>
- 1260 Tilg, H., Adolph, T.E., Trauner, M., 2022. Gut-liver axis: Pathophysiological concepts and clinical
1261 implications. *Cell Metab* 34, 1700–1718. <https://doi.org/10.1016/j.cmet.2022.09.017>
- 1262 Toledo, C., Salmerón, J.M., Rimola, A., Navasa, M., Arroyo, V., Llach, J., Ginès, A., Ginès, P., Rodés, J.,
1263 1993. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution
1264 and survival in patients treated with cefotaxime. *Hepatology* 17, 251–257.
- 1265 Tonkin-Hill, G., MacAlasdair, N., Ruis, C., Weimann, A., Horesh, G., Lees, J.A., Gladstone, R.A., Lo, S.,
1266 Beaudoin, C., Floto, R.A., Frost, S.D.W., Corander, J., Bentley, S.D., Parkhill, J., 2020. Producing
1267 polished prokaryotic pangenomes with the Panaroo pipeline. *Genome Biology* 21, 180.
1268 <https://doi.org/10.1186/s13059-020-02090-4>
- 1269 Tranah, T.H., Edwards, L.A., Schnabl, B., Shawcross, D.L., 2021. Targeting the gut-liver-immune axis
1270 to treat cirrhosis. *Gut* 70, 982–994. <https://doi.org/10.1136/gutjnl-2020-320786>
- 1271 Trebicka, J., Fernandez, J., Papp, M., Caraceni, P., Laleman, W., Gambino, C., Giovo, I., Uschner, F.E.,
1272 Jansen, C., Jimenez, C., Mookerjee, R., Gustot, T., Albillos, A., Bañares, R., Jarcuska, P., Steib,
1273 C., Reiberger, T., Acevedo, J., Gatti, P., Shawcross, D.L., Zeuzem, S., Zipprich, A., Piano, S., Berg,
1274 T., Bruns, T., Danielsen, K.V., Coenraad, M., Merli, M., Stauber, R., Zoller, H., Ramos, J.P., Solé,
1275 C., Soriano, G., de Gottardi, A., Gronbaek, H., Saliba, F., Trautwein, C., Kani, H.T., Francque, S.,
1276 Ryder, S., Nahon, P., Romero-Gomez, M., Van Vlierberghe, H., Francoz, C., Manns, M., Garcia-
1277 Lopez, E., Tufoni, M., Amoros, A., Pavesi, M., Sanchez, C., Praktiknjo, M., Curto, A., Pitarch, C.,
1278 Putignano, A., Moreno, E., Bernal, W., Aguilar, F., Clària, J., Ponzo, P., Vitalis, Z., Zaccherini, G.,
1279 Balogh, B., Gerbes, A., Vargas, V., Alessandria, C., Bernardi, M., Ginès, P., Moreau, R., Angeli,
1280 P., Jalan, R., Arroyo, V., PREDICT STUDY group of the EASL-CLIF CONSORTIUM, 2021. PREDICT
1281 identifies precipitating events associated with the clinical course of acutely decompensated
1282 cirrhosis. *J Hepatol* 74, 1097–1108. <https://doi.org/10.1016/j.jhep.2020.11.019>
- 1283 Trovato, F.M., Zia, R., Napoli, S., Wolfer, K., Huang, X., Morgan, P.E., Husbyn, H., Elgosbi, M.,
1284 Lucangeli, M., Miquel, R., Wilson, I., Heaton, N.D., Heneghan, M.A., Auzinger, G., Antoniades,
1285 C.G., Wendon, J.A., Patel, V.C., Coen, M., Triantafyllou, E., McPhail, M.J., 2021. Dysregulation

- 1286 of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic
1287 Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic
1288 Acid-Dependent Monocyte Activation. *Hepatology* 74, 907–925.
1289 <https://doi.org/10.1002/hep.31738>
- 1290 van den Berg, E.H., Flores-Guerrero, J.L., Garcia, E., Connelly, M.A., de Meijer, V.E., TransplantLines
1291 Investigators, Bakker, S.J.L., Blokzijl, H., Dullaart, R.P.F., 2023. High plasma levels of betaine,
1292 a trimethylamine N-Oxide-related metabolite, are associated with the severity of cirrhosis.
1293 *Liver Int* 43, 424–433. <https://doi.org/10.1111/liv.15310>
- 1294 Vergis, N., Atkinson, S.R., Knapp, S., Maurice, J., Allison, M., Austin, A., Forrest, E.H., Masson, S.,
1295 McCune, A., Patch, D., Richardson, P., Gleeson, D., Ryder, S.D., Wright, M., Thursz, M.R., 2017.
1296 In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection
1297 and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial
1298 DNA. *Gastroenterology* 152, 1068-1077.e4. <https://doi.org/10.1053/j.gastro.2016.12.019>
- 1299 Vital, M., Rud, T., Rath, S., Pieper, D.H., Schlüter, D., 2019. Diversity of Bacteria Exhibiting Bile Acid-
1300 inducible γ -dehydroxylation Genes in the Human Gut. *Comput Struct Biotechnol J* 17, 1016–
1301 1019. <https://doi.org/10.1016/j.csbj.2019.07.012>
- 1302 Walker, B.J., Abeel, T., Shea, T., Priest, M., Abouelliel, A., Sakthikumar, S., Cuomo, C.A., Zeng, Q.,
1303 Wortman, J., Young, S.K., Earl, A.M., 2014. Pilon: An Integrated Tool for Comprehensive
1304 Microbial Variant Detection and Genome Assembly Improvement. *PLOS ONE* 9, e112963.
1305 <https://doi.org/10.1371/journal.pone.0112963>
- 1306 Wang, Q., Chen, C., Zuo, S., Cao, K., Li, H., 2023. Integrative analysis of the gut microbiota and faecal
1307 and serum short-chain fatty acids and tryptophan metabolites in patients with cirrhosis and
1308 hepatic encephalopathy. *J Transl Med* 21, 395. <https://doi.org/10.1186/s12967-023-04262-9>
- 1309 Wick, R.R., Judd, L.M., Gorrie, C.L., Holt, K.E., 2017. Unicycler: Resolving bacterial genome assemblies
1310 from short and long sequencing reads. *PLOS Computational Biology* 13, e1005595.
1311 <https://doi.org/10.1371/journal.pcbi.1005595>
- 1312 Williams, H.R.T., Cox, I.J., Walker, D.G., Cobbold, J.F.L., Taylor-Robinson, S.D., Marshall, S.E., Orchard,
1313 T.R., 2010. Differences in gut microbial metabolism are responsible for reduced hippurate
1314 synthesis in Crohn’s disease. *BMC Gastroenterol* 10, 108. <https://doi.org/10.1186/1471-230X-10-108>
- 1316 Wong, F., Piano, S., Singh, V., Bartoletti, M., Maiwall, R., Alessandria, C., Fernandez, J., Soares, E.C.,
1317 Kim, D.J., Kim, S.E., Marino, M., Vorobioff, J., Barea, R. de C.R., Merli, M., Elkrief, L., Vargas,
1318 V., Krag, A., Singh, S.P., Lesmana, L.A., Toledo, C., Marciano, S., Verhelst, X., Intagliata, N.,
1319 Rabinowich, L., Colombato, L., Kim, S.G., Gerbes, A., Durand, F., Roblero, J.P., Bruns, T., Yoon,
1320 E.L., Giralá, M., Pysropoulos, N.T., Kim, T.H., Yim, S.Y., Juanola, A., Gadano, A., Angeli, P.,
1321 International Club of Ascites Global Study Group, 2021. Clinical features and evolution of
1322 bacterial infection-related acute-on-chronic liver failure. *J Hepatol* 74, 330–339.
1323 <https://doi.org/10.1016/j.jhep.2020.07.046>
- 1324 Y, Furusawa, Y, O., S, F., Ta, E., G, N., D, T., Y, N., C, U., K, K., T, K., M, Takahashi, Nn, F., S, M., E, M., S,
1325 Hino, K, A., S, O., Y, Fujimura, T, L., Jm, C., Dl, T., M, Tomita, S, Hori, O, O., T, M., H, K., J, K., K,

1326 Honda, K, Hase, H, O., 2013. Commensal microbe-derived butyrate induces the differentiation
 1327 of colonic regulatory T cells. *Nature* 504. <https://doi.org/10.1038/nature12721>
 1328 Zapun, A., Contreras-Martel, C., Vernet, T., 2008. Penicillin-binding proteins and beta-lactam
 1329 resistance. *FEMS microbiology reviews* 32. [https://doi.org/10.1111/j.1574-](https://doi.org/10.1111/j.1574-6976.2007.00095.x)
 1330 [6976.2007.00095.x](https://doi.org/10.1111/j.1574-6976.2007.00095.x)
 1331 Zhang, J., Kobert, K., Flouri, T., Stamatakis, A., 2014. PEAR: a fast and accurate Illumina Paired-End
 1332 reAd mergeR. *Bioinformatics* 30, 614–620. <https://doi.org/10.1093/bioinformatics/btt593>
 1333 Zhang, X., Bierschenk, D., Top, J., Anastasiou, I., Bonten, M.J., Willems, R.J., van Schaik, W., 2013.
 1334 Functional genomic analysis of bile salt resistance in *Enterococcus faecium*. *BMC Genomics*
 1335 14, 299. <https://doi.org/10.1186/1471-2164-14-299>
 1336 Zimmermann, P., Curtis, N., 2019. The effect of antibiotics on the composition of the intestinal
 1337 microbiota - a systematic review. *The Journal of infection* 79.
 1338 <https://doi.org/10.1016/j.jinf.2019.10.008>
 1339

1340 **Table 1:** Summary of clinical characteristics of patient and healthy participant study groups (all values
 1341 given as median [IQR])

Parameters		HC (n=40)	SC (n=15)	DC (n=81)	ACLF (n=57)	P value
General	Age (years)	36 (32-41)	59 (54-69)	55 (49-61)	49 (42-59)	<0.0001
	Male gender (n (%))	20 (50%)	11 (73.3%)	52 (64.2%)	36 (63.2%)	0.3287
	BMI (kg/m ²)	N/A	27.2 (23.5-32.6)	27.4 (24.0-30.5)	22.7 (20.8-23.2)	<0.0001
Aetiology of cirrhosis	Alcohol-related liver disease (n (%))	N/A	9 (60%)	57 (70.4%)	33 (57.9%)	0.2950
	Drinking / Alcohol actively drinking (n (%))	N/A	0	12 (21%)	19 (57.6%)	0.0002

	Abstinent	Alcohol abstinent (n (%))	N/A	9 (100%)	45 (79%)	14 (42.4%)	
	Metabolic-dysfunction associated steatotic liver disease (MASLD) (n (%))		N/A	3 (20%)	7 (8.6%)	6 (10.5%)	0.4181
	Cholestatic/autoimmune (n (%)): Primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Alagille syndrome, biliary atresia, and autoimmune hepatitis (AIH).		N/A	1 (6.7%)	6 (7.4%)	11 (19.3%)	0.0832
	Metabolic (number (%)): Wilson's disease, haemochromatosis and alpha-1-antitrypsin (A1AT) deficiency		N/A	1 (6.7%)	5 (6.2%)	3 (5.3%)	0.9663
	Other (n (%)): 'Cryptogenic', treated viral hepatitis, chronic veno-occlusive related-cirrhosis (Bud Chiari), chronic porto-mesenteric venous insufficiency cirrhosis, and drug induced		N/A	1 (6.7%)	6 (7.4%)	4 (7%)	0.9928
Clinical features at enrolment	Temperature (°C)		N/A	36.5 (36.3-37.2)	36.7 (36.4-37.0)	36.5 (36.1-37.1)	0.2121
	Presence of ascites (n (%))		N/A	5 (33.3%)	58 (71.6%)	55 (96.5%)	<0.0001
	Ascites grade (n (%))	Small	N/A	5 (100%)	25 (43.1%)	35 (63.6%)	0.0107
Moderate/Severe		N/A	0	33 (56.9%)	20 (36.4%)		


	Presence of Hepatic encephalopathy (n (%))		N/A	1 (6.7%)	35 (43.2%)	49 (86%)	<0.0001
	Hepatic encephalopathy grade	1-2	N/A	1 (100%)	35 (43%)	24 (49%)	<0.0001
		3-4	N/A	0	0	25 (51%)	
	Mean arterial pressure (mmHg)		N/A	95 (87-100)	81 (76-89)	75 (70-82)	<0.0001
	Presence of bacterial infection (n (%))	Blood culture	N/A	0	2 (2.5%)	3 (5.3%)	0.4996
		Urine culture	N/A	0	5 (6.2%)	2 (3.5%)	0.5114
Heart rate (beats per minute)		N/A	76 (65-82)	77 (60-88)	87 (78-95)	0.0010	
Antibacterial therapy at enrolment (number (%))	Antibiotics – any		N/A	3 (20%)	37 (45.7%)	52 (91.2%)	<0.0001
	Antifungal – any		N/A	0	2 (2.4%)	20 (35.1%)	<0.0001
	Rifaximin		N/A	1 (6.7%)	10 (12.4%)	2 (3.5%)	0.2583
	Fluoroquinolone (Norfloxacin, Ciprofloxacin)		N/A	0	8 (9.9%)	0	0.0702
Other pharmacotherapy at enrolment (number (%))	Proton pump inhibitors (Omeprazole, Lansoprazole)		N/A	10 (66.7%)	44 (54.3%)	36 (63.2%)	0.4721
	Lactulose		N/A	2 (13.3%)	30 (37.0%)	2 (3.5%)	0.1234
	Non-selective beta-blockers (Propranolol, Carvedilol)		N/A	6 (40%)	34 (42.0%)	14 (24.6%)	0.1001

	H2 antagonist (Ranitidine)	N/A	0	3 (3.7%)	0	0.2567
Laboratory parameters	Haemoglobin (g/dl)	N/A	130 ± 25	112 ± 21	92 ± 15	<0.0001
	Leukocyte count (x10 ⁹ /L)	N/A	4.46 (3.96-6.11)	5.57 (4.25-7.39)	9.74 (6.54-14.57)	<0.0001
	Neutrophils (x10 ⁹ /L)	N/A	2.92 (2.14-3.69)	3.70 (2.37-5.29)	7.70 (4.85-12.21)	<0.0001
	Platelet count (x10 ⁹ /L)	N/A	111 (99-151)	106 (75-165)	86 (56-115)	0.0061
	INR	N/A	1.15 (1.10-1.29)	1.44 (1.29-1.75)	2.09 (1.69-2.93)	<0.0001
	Serum creatinine (µmol/L)	N/A	73 (66-84)	77 (57-94)	135 (87-206)	<0.0001
	Serum bilirubin (µmol/L)	N/A	20 (11-25)	41 (24-72)	209 (84-371)	<0.0001
	Albumin (g/L)	N/A	39 ± 4	33 ± 6	27 ± 7	<0.0001
	C-reactive protein (mg/L)	N/A	5.5 (2.3-11.1)	11.7 (3.4-32.9)	47.3 (23.7-70.7)	<0.0001
	Blood lactate (mmol/L)	N/A	1.4 (1.2-1.9)	1.5 (1.2-2.1)	2 (1.6-3.2)	0.0006
	Venous ammonia (µmol/L)	N/A	61 (28-88)	53 (33-72)	68 (47-107)	0.0710
Disease severity & prognostic scores	Child Pugh	N/A	6 (5-6)	8 (8-10)	12 (11-13)	<0.0001
	MELD	N/A	9 (8-11)	16 (12-23)	34 (29-39)	<0.0001

	UKELD	N/A	49 ± 3	55 ± 5	61 ± 6	<0.0001
	CLIF-C-AD	N/A	N/A	49 (43-53)	N/A	—
	CLIF-C-ACLF	N/A	N/A	N/A	54 (46-66)	—
	CLIF-OF	N/A	N/A	7 (6-8)	13 (11-15)	<0.0001
Transplant-free survival	30-day	N/A	0	72 (88.9%)	24 (42.1%)	<0.0001
	90-day	N/A	0	63 (77.8%)	14 (24.6%)	<0.0001



1342

1343 **Supplementary data**



1344


1345 **Supplementary Figure 1.** Representative FACS gating strategy used to identify CD14+ monocytes in
 1346 peripheral blood mononuclear cells (PBMCs) with isotype control used to determine the IL-6-
 1347 producing monocytes (%) in response to LPS stimulation. Side scatter (SSC), forward scatter (FSC).
 1348



1349

1350 Supplementary Figure 2. Clinical metadata associated with cirrhosis patient gut microbiota
1351 composition.


1352 (A) Results of envfit analysis showing clinical metadata variables significantly associated with
1353 microbiota composition after correction for multiple testing using False Discovery Rate. Bars show
1354 the R² (squared correlation coefficient) of the correlation and numbers on bars show adjusted P-
1355 values. (B) NMDS ordination plot showing gut microbiota composition of individual liver patients with
1356 the ten clinical metadata variables with the highest R² overlaid.



1357

1358 Supplementary Figure 3. Individual bile acid concentrations by cirrhosis severity and correlations
 1359 between genus proportion and bile acids.


1360 (A) Glycochenodeoxycholic acid, (B) Glycocholic acid, (C) Tauroursodeoxycholic acid, (D)
1361 Glycoursodeoxycholic acid, (E) Deoxycholic acid, (F) Glycodeoxycholic acid, (F) Pearson correlations
1362 between normalised plasma bile acid concentrations and normalised genus relative abundance using
1363 a Pearson correlation. P-value: * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$. Significance corrected for
1364 multiple testing.



1365

1366 Supplementary Figure 4. Individual urinary metabolites by cirrhosis severity and correlations
 1367 between genus proportion and plasma metabolites.

1368 (A) Creatinine, (B) Citrate, (C) Dimethylamine, (D) Formate, (E) Mannitol, (F) Correlations between
 1369 normalised urinary metabolites and normalised genus relative abundance using a Pearson
 1370 correlation. P-value: * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$. Significance corrected for multiple testing.




1371

1372 Supplementary Figure 5. Individual plasma metabolites by cirrhosis severity and correlations
 1373 between genus proportion and plasma metabolites.

1374 (A) Phenylalanine, (B) Citrate, (C) Formate, (D) Lipid, (E) Valine, (F) Isoleucine, (G) Correlations
 1375 between normalised plasma metabolites and normalised genus relative abundance using a Pearson
 1376 correlation. P-value: * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$. Significance corrected for multiple
 1377 testing.

1378



1379

1380 Supplementary Figure 6. Correlations between genus proportion and monocyte stimulation.

1381 Full correlations between the top 15 most abundant genera and TNF-alpha, IL-6, and HLA-DR


1382 percentage in (A) Unstimulated, (B) LPS stimulated, (C) PAM3 stimulated, and (D) CpG simulated

1383 monocytes. Correlations between normalised plasma metabolites and normalised genus relative

1384 abundance using a Pearson correlation. P-value: * = $p < 0.05$, ** = $p < 0.01$. Significance corrected for

1385 multiple testing.

1386



1387

1388 Supplementary Figure 7. Aetiology associations with overall microbiota composition and

1389 *Enterococcus* abundance.

1390 (A) NMDS clustering of overall genus level faecal microbiota composition based on a Bray-Curtis
1391 matrix showing patient samples with patient aetiology condensed to eight groups for the purposes
1392 of analysis showing a lack of clustering by aetiology (PERMANOVA: $P = 0.1$). (B) Box plots show full
1393 patient aetiology groups with faecal *Enterococcus* abundance grouped by illness severity.